# **Protocol S1:**

Large-scale computational mapping and experimental validation of  $Escherichia\ coli$  transcriptional regulatory interactions from a compendium of expression profiles

Jeremiah J. Faith, Boris Hayete, Joshua T. Thaden, Ilaria Mogno, Jamey Wierzbowski, Guillaume Cottarel, Simon Kasif, James J. Collins, and Timothy S. Gardner

Manuscript in Press at PLoS Biology

**Summary**. This supplement provides additional figures and results on the comparison of network algorithms, additional discussion of our conclusions regarding optimal experimental design for network inference, and additional results on global properties of the inferred networks. We also describe methods not provided in the main text.

# **Supplementary Results**

# Verification of array data normalization and consistency

The algorithms applied in this study require the consolidation of results from disparate sources including different experimenters and different laboratories. To minimize the impact of experimentally induced error, we used only expression data collected on a single platform, the Affymetrix Antisense2 microarray. Nevertheless, we evaluated whether such data could be reliably integrated and still preserve quantitative information on expression levels of transcripts in *E. coli* across many conditions.

After normalization, our analysis shows that coordinated expression responses in the compendium are observed regardless of the laboratory or individual running the experiment, verifying the consistency of the array platform and normalization procedure. Figures S5a, S5b, and S6b show relationships between different transcription factors and their known targets that are characteristic of the data in our E. coli microarray compendium. The wide range of expression levels for the genes presented in Figure S5 result from the cell's response to the different environmental and genetic perturbations assayed in the compendium. In each plot, the expression level of the regulated gene increases with the expression level of its regulator. For example, Figure S5a shows the expression levels of recA, an important gene involved in the SOS-response to DNA damage, and of lexA, the primary transcription factor of the SOSresponse [1]; each gene is highly expressed only when a DNA-damaging agent is present in the growth media. A similar situation occurs for the switch-like arabinose-induced response shown in Figure S5b. Although some lab-to-lab variation is observed in the expression response under similar conditions, we conclude that the dominant changes are due to biological responses not to interlab variations. Thus we can reliably combine the data from disparate sources into a single compendium for quantitative analysis.

# **Comparison of network algorithm variants**

In Figure S7, we present a comparison of the original published versions of these algorithms, as well as modified versions of the algorithms. We developed the modified versions of the algorithms in order to improve their performance on the *E. coli* data.

# Summary of tested algorithms

We study two major groups of network inference algorithms. In the first group, which is represented by multivariate approaches including Bayesian networks and regression-based methods, the algorithm considers one or more potential regulators for each gene and the functional form of that regulation. Although this class of algorithms directly addresses the problem of determining logic gates and combinatorial regulation, it creates a combinatorial optimization problem that quickly becomes infeasible to compute for large networks. To make the problem computationally tractable, we allowed at most two regulators per gene when applying Bayesian or regression network algorithms (Figure 2b and Figure S7a). The linear regression network approach slightly outperforms the Bayesian network approach because the

regression approach allows cycles, of which there are several in RegulonDB. Both methods perform significantly better than random.

The second group of algorithms we tested takes a pairwise approach where each potential interaction between a regulator and a target is considered independently. These methods do not explicitly model the functional form of a combinatorial interaction, but they are more computationally tractable and have no problems scaling to genome-sized networks. In this group we tested relevance networks, ARACNe, and CLR (discussed in main text).

By choosing a high mutual information threshold, relevance networks algorithm achieves precision levels near 90% and obtains reasonable sensitivity (Figure 2b). We also found that Relevance networks constructed using correlation (specifically correlation-squared) as a metric of dependency between two variables outperform networks constructed using mutual information (Figure S7b). This occurs, in part, because mutual information depends on the entropy of the gene pair. Normalization of the mutual information to the minimum entropy of the pair improves the performance (Figure S7b).

One difficulty for relevance networks, and inference algorithms in general, is distinguishing causality from correlation. The ARACNe algorithm attempts to address this problem by applying the Data Processing Inequality to the relevance network to prune away indirect regulatory influences [2,3]. This method was successfully applied to microarray data from human B-cell populations to infer known and novel regulatory interactions, particularly those related to the proto-oncogene *MYC* [4]. We developed a probabilistic ARACNe that outperforms the original and several other variants of ARACNe (Figure S7c) on the *E. coli* compendium, but no version of ARACNe performed as well as the simpler relevance networks algorithm (Figure 2b). The DPI pruning method that underlies ARACNe and probabilistic ARACNe preferentially eliminates direct feedback and feedforward loops. However, such loops are common in microbial regulatory networks [5]. Thus the DPI pruning approach places unrealistic constraints on the resulting regulatory network, which likely accounts for its diminished performance.

Below we provide further rationale for development and implementation of algorithm variants tested in this study.

#### Bayesian networks and linear regression networks

We applied several published Bayesian network algorithms [6-8] to the full *E. coli* compendium. However, none of the algorithms we tested were able to complete their computations due to memory limitations, or run-time errors resulting from the large scale of the data set. These problems are likely due the combinatorial complexity inherent in Bayesian network analysis approaches. To address this we implemented our own Bayesian network algorithm, using a multivariate linear model of combinatorial regulatory interactions, and limited the in-degree of the inferred network to two in order to maintain computational tractability. We also implemented a linear regression network that determines the regulators of each gene independently, and did not assemble the resulting network into a globally optimally network. Therefore the linear regression network, unlike the Bayesian network, permitted the inference of cycles. Like the Bayesian network algorithm, the linear regression network used a multivariate linear model of combinatorial interactions, and also limited the in-degree of the inferred network to two.

The linear regression network algorithm obtained higher performance than the Bayesian network algorithm, presumably because it permitted cycles (Figure S7a), although the resulting network was no longer a rigorous a probabilistic description of the network. Performance

improved for the linear regression network and the Bayesian network when we applied each algorithm four times, each time using data normalized with a different one of the four methods, and then averaged the resulting networks (Figure S7a).

#### Relevance networks

For relevance networks, we found that using correlation [9] improved the performance over the original method, which used mutual information (Figure S7b) [10]. This occurs, in part, because mutual information depends on the entropy of the gene pair. Normalization of the mutual information to the minimum entropy of the pair improves the performance (Figure S7b). Knowledge of operons provided slight boosts in recall for certain precision ranges for relevance networks (Figure S7b blue curve; see the CLR section below for the method for using knowledge of operons).

#### **ARACNe**

With ARACNe, we considered whether it was more effective to apply the DPI pruning after applying the constraint allowing only transcription factor/gene interactions. We found that application of DPI pruning after the constraint lowered performance of the algorithm (data not shown). Thus, for all results presented here, we applied the DPI pruning *before* applying the transcription factor constraint.

Using a spline-based estimation of mutual information improved the performance relative to the original ARACNe (Figure S7c magenta) but did not allow higher recall. Performance improved further by incorporating a probabilistic data processing inequality (DPI). And like the Bayesian network algorithm, ARANCe performance improves when it is run separately on data normalized by four different microarray normalization algorithms and the resulting four networks are averaged.

#### **CLR**

CLR's background correction procedure allows determination of a gene-specific significance of mutual information. Other gene-specific background correction approaches have been proposed previously, including the analytical Roulston method [11] and the empirical shuffling approach, which builds the background distribution for a given mutual information score by randomly permuting the two genes' expression profiles many times. Though gene-specific, the Roulston and shuffling methods are not context-dependent; they compute the significance of mutual information using only the data for a particular pair of genes. In contrast, CLR computes the significance of mutual information by assembling a background distribution from the mutual information scores of all other microarray probe sets in the compendium.

CLR outperforms the Roulston approach (Figure S7d). We do not show results based on the shuffling method, as it was too computationally demanding to achieve the necessary number of permutations for a large network. Nevertheless, we confirmed that the Roulston metric and the shuffling approach converge to similar p-values and overall performance (by running 30 shuffles on a test network of 1211 genes).

The CLR algorithm was applied using both un-normalized and minimum-entropy-normalized mutual information (see the Relevance networks section above). Unlike relevance networks, CLR showed only modest improvement when mutual information was normalized (Figure S7d red), suggesting that the CLR procedure itself normalizes mutual information.

In relevance networks, correlation performed better than mutual information at high

sensitivities. Thus, we also applied the CLR background correction method to correlation-based relevance networks. However, mutual information-based CLR outperformed correlation-base CLR in all cases.

Two procedures were tested to determine if prior knowledge of operon structure would improve performance. In the first method, we grouped genes into operons and gave each gene in the operon the median CLR score of the genes in the operon. In the second method, the genes grouped into operons were assigned the maximum CLR score of the genes in the operon. The median CLR score operon method produced negligible improvement (Figure S7d green). The maximum CLR score operon method slightly boosts recall across almost the entire range of precision values (Figure S7d blue). This operon-based performance boost is only possible if operon structure is known *a prior*. For most genes and most novel organisms, operon structure is not known and may be condition-dependent. Thus, we used the CLR without operon data for all further analysis in this study.

# **Experimental Design for Network Inference**

Our compendium was not purpose-built for large-scale network inference. It contains conditions reflective of the interests of the contributing laboratories. However, by determining the conditions and factors in these data that are most informative to network inference, we may gain insight into the design of future microarray compendiums constructed with the intent of inferring the largest, most precise regulatory network with the fewest microarrays.

## Diversity of the compendium influences network inference recall

We expected the number and phenotypic diversity of expression profiles in the compendium to significantly impact the recall of the CLR algorithm. To test the influence of these factors on the inferred network, we identified the smallest set of microarrays sufficient to reconstruct a network equal in recall and precision to a network constructed with all 445 arrays. We used clustering to select the most dissimilar subset of expression profiles from the compendium and measured the performance of the CLR algorithm on this subset. We also analyzed subsets of randomly chosen expression profiles and sets of the most similar profiles.

As expected, the most dissimilar set provided the best performance using the fewest profiles. Using this set, only 60 profiles were required to infer the network with performance equal to that obtained with the entire 445 profiles in the data set (Figure 2c). Each of the 60 conditions is selected from a different cluster where each cluster represents groups of experiments from related environmental conditions (Table S4). Thus, the 60 most diverse conditions are a sufficient representation of the entire dataset. Replication of samples and in-depth sampling of related conditions do not substantially improve the results, as the remaining arrays provide mostly redundant information that does not dramatically increase or decrease performance

Network inference experimental designs have used environmental perturbations [4,12], genetic perturbations [13-18], or some combination of the two [19,20]. Our results suggest that profiling gene expression in diverse environmental conditions relevant to an organism's life cycle may be the most efficient strategy to systematically map transcriptional regulatory networks in microbes. Generally, large environmental perturbations, like media changes and addition of drugs, appear to be more informative to our regulatory pathway inference algorithm than genetic perturbations, such as gene overexpressions and knockouts. Genetic perturbations can be valuable, but they often produce few changes in expression because the scope of their influence will depend on network topology, redundancies in the network and may be condition

dependent. Environmental perturbations, on the other hand, are more likely to produce rich expression responses because they often invoke changes in multiple and overlapping pathways.

Additional support for these conclusions is provided by the examples in Figure S5, which show that regulatory relationships become detectable as soon as samples of the relevant condition are added to the compendium. The figures show that LexA targets are only detectable when SOS response conditions are sampled and AraC targets are detectable only when arabinose-metabolizing conditions are sampled. The Lrp regulon (Figure S6b) provides an additional example. When using only those profiles sampled from cells grown in rich (LB) media, Lrp (a transcription factor that is highly expressed in minimal media) had no inferred targets. Most of the known Lrp targets had a weak, incorrect correlation to LexA (Figure S6a inset), but these correlations were correctly eliminated by CLR. Only when the arrays from minimal media were combined into the same dataset did the CLR algorithm successfully identify the targets of Lrp (Figures S6a, S6b, 3, and S3b). This suggests that the expression diversity is of primary importance of identifying regulatory interactions. It also indicates that a network map can be built incrementally by successively profiling the expression of an organism in un-sampled or undersampled physiological states.

We also examined the impact of using time-series on the algorithm performance. Among the 445 microarrays, there are 36 arrays (including replicates) with time-points 30 minutes apart and an additional 24 microarrays with close time-points (12-24 minutes apart). We note that none of the tested algorithms explicitly accounted for dynamic expression measurements (all assumed steady-state data). Thus, we expected that exclusion of the time-series might positively impact our results. However, we applied the CLR algorithm to the compendium with all time-series data removed and found that the performance of the algorithm decreased. To identify what aspect of the time-series data contributed most to network inference, we analyzed the minimal set of 60 experiments needed to reconstruct the network. These experiments generally contained only the first and last time points in each time series, presumably representing extremes of the response. This result again supports the conclusion that phenotypic diversity is most important for network inference.

Note, it is possible that intervening time-points contain information useful for network inference, but because the algorithms do not account for dynamic changes, they cannot benefit from such information. Approaches such as Dynamic Bayesian Networks (DBNs) [3] or smoothing approaches [21,22], might make better use of time-series information. A publicly available DBN algorithm was applied to the data, but did not successfully execute due to problems with the scale of the dataset. Smoothing approaches were not applied due to the ambiguity in selecting smoothing parameters, and the potential for introducing data artifacts in undersampled temporal data.

## Optimizing experimental design for network inference

How might appropriate conditions be identified for testing? Analysis of an organism's natural environment provides a rich source of potential test conditions. For example, the natural environment of *E. coli*, the gut, provides a vast set of potential perturbations in the form of food sources, bile, immune factors, antimicrobial peptides, and secreted factors from other microbes that have only recently begun to be studied in the literature [23-26]. Underrepresented conditions in the compendium may also be identified based on the GO function categories with the greatest number of unperturbed transcription factors (Table S5) or genes (Table S6) in the current compendium.

Such a broad approach to sampling the physiology of a microbe presents an experimental challenge because an unmanageable number of conditions are conceivable. Which ones should be sampled, and in which combinations, to obtain the most informative data set? A practical solution to this problem may be found in the statistical design of experiments pioneered 60 years ago by Ronald Fisher. Fisher's approach addressed the question of how to obtain reliably the most information with the fewest experiments [27,28]. Studies employing factorial designs, fractional factorial designs, or more recent Bayesian designs, are already commonplace in industrial research and optimization. These or similar methods have had proponents in the field of microarrays [29,30], but have received little attention in larger microarrays studies. These designs should make the generation of a compendium covering the phenotypic space of an organism a more manageable task.

### Estimating the number of experiments needed to infer a complete microbial network

Though highly speculative, it is interesting to estimate the number of experiments needed to infer a complete network of transcription interactions based on expression data. We can arrive at this number by extrapolating the sensitivity obtained with the CLR algorithm. Assuming that the each experiment processed by the CLR algorithm will reveal an equal fraction of all interactions, q, we can estimate the probability,  $p_N$ , of finding an interaction after N experiments:  $p_N = 1 - (1-q)^N$ . The sensitivity of the algorithm is equal to  $p_N$ . At 80% precision with 60 experiments, the CLR algorithm achieves a sensitivity of:  $p_{60} = 4.5\%$ . Thus we have:  $p_{60} = 1 - (1-q)^{60}$  giving q = 0.000769. By extrapolating using this value of q, we can project the number of experiments needed for any sensitivity  $(p_N)$  as  $N = 60 \log(1-p_N)/\log(1-p_{60})$ . For of  $p_N = 70\%$ , this gives: N = 1565 experiments. Similarly, for sensitivities of 80%, 90% and 95% (at 80% precision), we estimate that 2093, 2994 and 3895 experiments would be required. At 60% precision, these numbers become 1108, 1482, 2120, and 2758 experiments at 70%, 80%, 90%, and 95% sensitivity.

We acknowledge that these projections are speculative and likely an underestimate. They assume that (1) all experiments are equally informative and provide as much information as the best experiments in our dataset, and (2) each experiment will elucidate an independent set of interactions. Such an optimal selection is not necessarily possible in a prospectively designed set of experiments. It might also be more accurate to assume that the information value of experiments will diminish as more experiments are performed, because more informative conditions will be selected first. However, the rate at which the information content of the experiments declines (if at all) is unknown. Also, we do not know the relative information value of the experiments in our existing data set, so it would be unrealistic to attempt to estimate this rate from the existing experiments. Thus, we cannot extrapolate using this more sophisticated model. In addition, all transcription factor/target interactions are not likely to be identifiable from expression data alone (see below).

#### Limitations of network inference using microarray data

Although most microbial transcription factors exhibit some modulation of transcription, there may be regulators that are expressed constitutively without any condition-dependent regulation. Modulation of such factors could occur only post-transcriptionally. The targets of such regulators cannot be detected by any algorithm that relies on microarray expression profiles alone, unless they are artificially modulated [31]. Our analysis of existing regulatory pathways suggest that such cases of constitutive expression in microbes are rare; there is nearly always

some transcriptional regulation, often through direct or indirect feedback loops or at the level of sigma factor modulation. Nevertheless, detecting the targets of such constitutively transcribed regulators will require an alternative approach based on mass spectrometry, chromatin immunoprecipitation, or synthetic modulation of the regulators. Additionally, current limitations of microarray profiling technology such as the lack of sensitivity for low-expressed genes may limit network inference on this subset of genes, unless the array technology is improved [32].

With all statistical approaches there is a difficult task of differentiating between correlation and causation. Some network inference methods aim to identify causation from the expression data itself by placing assumptions on the network structure. The alternative and best means we have to differentiate between direct regulation and correlated expression is to constrain the network using prior knowledge of transcription factor identity. By allowing only transcription factors to be regulators in the network, we can remove a large number of interactions that are not direct physical links between a transcription factor and its target gene. This prior information also provides direction to all edges except those between two transcription factors.

This constraint, used for all of the algorithms we tested, relies on accurate annotation of transcription factors to determine what genes to define as regulators in the network. Transcription factor identification by sequence analysis is a mature field of bioinformatics. Existing algorithms generate these lists with high sensitivity, but any further improvements in the precision of the list would potentially improve the inferred transcriptional regulatory map as well.

# Scale-free properties of the inferred networks

Previous studies into global properties of regulatory networks in *E. coli* and *Saccharomyces cerevisiae* have shown a scale-free distribution of out-degree connectivity characterized by a large number of scantly connected nodes and a few highly connected nodes termed hubs [33]. A scale-free distribution was also found in the network inferred by ARACNe using human B cell data [4]. A concern with the background distribution model used by CLR is that it may bias the out-degree of each gene by permitting too many targets for the low-degree nodes and pruning too many targets for the hubs. However, the distribution of out-degree for transcription factors in the CLR inferred network is in fact scale-free (Figure S8). Although the network's hubs are not as large as some of the RegulonDB hubs, some CLR hubs still have more than fifty targets. The CLR network actually fits a scale-free distribution better than RegulonDB, as the largest hubs in RegulonDB are outliers in the scale-free distribution. All of the other algorithms tested in this study also infer scale-free networks, but all infer smaller hubs on average than the CLR algorithm. These results suggest that if there is any bias in the networks inferred by CLR due to its background distribution model, the bias does not cause a deviation from a scale-free network and imparts less bias on the maximum inferred out-degree than any other tested algorithm.

# Combinatorial Regulation in the CLR Regulatory Map

As compendiums grow with the reduced cost of microarrays, network inference algorithms will uncover more of the intricate combinatorial regulatory schemes of cells. Currently, there are 824 cases within the known *E. coli* regulatory network, where a gene is regulated by 2-10 transcription factors [5,34]. By adding our new interactions whose precision is 80% or greater, our study increases the number of combinatorially regulated genes by nearly 50.

A simple way to classify combinatorial interactions is to discretize the expression values of each gene and transcription factor into two Boolean states (Figure S9a). The set of all states (the

"combinatorial state space") of the transcription factors and their target under study form a truth table that determines the approximate combinatorial logic function of the transcription factors. For example, in the case of two transcription factors targeting one gene, if the target gene is highly expressed only when both transcription factors are highly expressed, the regulation would be classified as AND-like; whereas if the target gene is highly expressed when either or both of the regulators are highly expressed, the regulation would be classified as OR-like.

Most of the 67 cases of combinatorial regulation involving 2-3 transcription factors, in which at least one of the regulatory interactions was also predicted by our algorithm (the other edges were known edges in RegulonDB), have insufficient data points in the compendium to allow the determination of the logic gate. The combinatorial regulators perturbed in the compendium are usually expressed in the same operon, and thus show high expression covariance leading to undersampling of the combinatorial state space (Figure S9b). Complex combinatorial regulation at such promoters may not occur under normal environmental conditions, or may not be detectable via RNA expression data alone.

There are, nevertheless, some cases where evidence of combinatorial logic can be observed in the expression data. Two cold-shock proteins, CspA and CspG, are identified by CLR to regulate ddg, a gene which encodes an enzyme that incorporates palmitoleate instead of laurate into lipid A when E. coli undergo cold-shock or growth at below  $12^{\circ}C$  [35]. The compendium data suggest that the two regulators operate by AND-like logic (Figure S9c and S9d). CspA and CspG are two of the four cold-shock proteins in a quadruple deletion that results in a cold-temperature dependent growth defect [36]. Our results are in concordance with the current working hypothesis that the cold-shock genes evolved by duplication of the cspA family genes whereupon the duplicated genes each acquired a more specific role [36]. Our results suggest that CspA is expressed under a large range of temperature conditions, and its presence is required in addition to the more specifically expressed CspG protein to induce the expression of ddg, which can then incorporate palmitoleate into lipid A in place of laurate.

# **Supplementary Methods**

## **Functional Enrichment**

We obtained gene functional annotations and ontology hierarchies from EcoCyc (annotations were from Gene Ontology Consortium, Enzyme Commission (EC), and other ontologies). We included all ancestors of each term associated with a particular gene. We determined enrichment with a hypergeometric distribution by calculating the p-value of the given number of hits for each term based on the query size, the number of genes in the genome, the number of genes in the query with the given association and the number of genes in the genome sharing that association. To ensure that single-gene hits would not provide enrichment to rare categories, we required at least two genes in a query set to map to the same term.

## **Motif Detection**

For motif discovery, we first pruned the network at the 60% confidence threshold. We grouped the target genes of each transcription factor into operons using the known and putative operons in RegulonDB [34]. To attain the statistical significance necessary for sequence alignment, we only included transcription factors regulating at least five operons. We constructed multiple alignments of the promoter regions using the MEME multiple alignment system version 3.5.0 [37]. We obtained the operon, predicted operon, and transcription start site annotation from the

RegulonDB website. Having obtained the transcription start site, we took 150 bp upstream of this site to be the promoter. When another gene was found less than 150 bp upstream of the transcription start site, we truncated the promoter length to the end of the preceding gene. A background model was built using tri-nucleotide frequencies from all promoter regions. This model was supplied to MEME as the background model for estimating the likelihood of motif occurrence. MEME was constrained to find any number of repetitions of one motif, occurring on the same strand within each promoter. Motif width and other settings were left to default values.

To further assess the significance of each motif, we shuffled the nucleotides of every promoter 100 times and ran MEME on each shuffled dataset, recording the e-value of the top motif each time. These e-values followed a near-normal distribution, skewed by the difference between the common true motif nucleotide distribution and the background distribution. We fit the distribution of shuffled motif e-values to the normal distribution and approximated the quality of the "true" motif as the z-score of that motif's e-value calculated from this 'shuffle' background.

#### Verification of detected motifs

We developed a simple algorithm to compare motifs identified by the above procedure to position weight matrices found in PRODORIC [38]. The nucleotide occurrence probability tables reported by MEME were converted to position weight matrices scored in bits (log2), with values of 4 bits of information or less per position. We compared every possible overlap of 10 to 16 positions between each inferred motif and all known motifs. The similarity between the inferred motif and a known motif was scored as:

$$\sum_{pos}$$
 2- | MEME  $\_motif_{pos}$  -  $DB \_motif_{pos}$  |

This score is highest when the position weights for MEME inferred motifs are identical to a known motif in PRODORIC. This procedure allowed ranking of known motifs with respect to the one recovered in our study.

## **Chromatin Immunoprecipitation**

Transcription factors assayed by ChIP-PCR were cloned into TOPO (Invitrogen) IPTG inducible vectors containing an  $Xpress^{TM}$  epitope. The plasmid was transformed into  $E.\ coli$  strain MG1655 and verified by DNA sequencing.

Transcription factor:DNA complexes were immunoprecipitated using a modification of the protocols of Lin and Grossman [39] and Upstate (http://www.upstate.com/). Six replicates were performed for each transcription factor. Cells were diluted 1:100 from overnight cultures into 50 ml of LB with 0.5% glucose in a 250 ml flask and grown to an OD600 of around 0.5. A 15 ml sample was taken from each flask and 400 µl of 37% formaldehyde was added (final concentration 1%). Protein:DNA constructs were cross-linked for 10 minutes at room temperature followed by two washes in ice-cold PBS.

Cells were lysed by incubating samples at 37°C for 30 minutes in 500 µl of lysis buffer (10 mM Tris, 50 mM NaCl, 10 mM EDTA, 20% sucrose, and 4800 units of freshly added Epicenter Ready-lyse lysozyme), followed by addition of 500 µl of 2X IP buffer (200 mM Tris, 600 mM NaCl, 4% Triton X-100, 1 mM fresh PMSF, and 4 µg/ml RNase Cocktail [Ambion]) and

incubation for 10 minutes at 37°C with shaking. Lysates were sonicated 4 x 30 seconds with a Branson sonicator on 20% percent power to shear DNA to an average size of 500bp.

A 100 µl sample of the sheared lysate was removed, crosslinks were reversed, and the sheared DNA was purified by phenol:chloroform extraction and ethanol precipitation to determine starting DNA concentration and to verify the shearing size. This purified sheared DNA also served as a positive control for the qPCR step downstream. Three samples, each containing 25 µg of sheared DNA, were taken from the remaining 900 µl of sheared lysate, and they were diluted 1:10 in dilution buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM Tris [pH 8], 1 mM PMSF). Two micrograms of antibody specific to the transcription factor epitope tag (Anti-Xpress<sup>™</sup>) were added to the first sample. Two micrograms of an unrelated antibody (Anti-Myc) were added to the second sample to serve as a negative control. The third sample contained no antibody and served as an additional negative control. All three samples were rotated at 4°C overnight. The following morning, protein A/G agarose beads were added to the samples containing the transcription factor-antibody complexes. The beads were then washed in increasingly stringent conditions (by increasing and changing salts) to remove factors binding non-specifically to the beads or antibody. Protein:DNA complexes were removed from the beads by addition of 500 µl of fresh elution buffer (1% SDS, 100 mM NaHCO<sub>3</sub>) and rotation at room temperature for 15 minutes. Cross-links were reversed by addition of 10 µl of 5M NaCl and incubation at 65°C overnite. The precipitated DNA was purified by phenol:chloroform extraction and ethanol precipitation.

Enrichment of DNA sequences bound to a particular transcription factor was determined by comparing the cycle (Ct) when each qPCR reaction crosses a threshold in the middle of the exponential amplification phase of the reaction. Reactions were performed using an ABI Prism 7900HT with ABI Sybr Green PCR master mix, 150 nM of each primer, and immunoprecipitated DNA template. The log fold-change in enrichment was calculated as  $\log((1+E_i)^{C_i-U_i})$ , where  $E_i$ is the median efficiency of the PCR primers for gene i, C<sub>i</sub> is the Ct value for the DNA enriched using correct antibody for the transcription factor regulating gene i, and  $U_i$  is the Ct value for the DNA enriched using unrelated antibody for the transcription factor regulating gene i. To make the  $C_i$ - $U_i$  enrichment values comparable across each set of replicates, the values for each set of replicates were scaled by the median enrichment value of that set. Outlier enrichment values for each promoter were removed by Grubbs test. Interactions were declared significant when the log fold-change in enrichment for a given gene was significantly greater, by a t-test (P<=0.01) and a non-parametric rank sum test (P<=0.01), than a set of 66 samples taken from the promoter regions of 11 random genes not regulated or inferred to be regulated by the transcription factor being tested. The interactions for Lrp were also tested in Davis minimal media. Lrp interactions enriched in either media were declared significant.

## qPCR Analysis of fecA Combinatorial Regulation

Strain MG1655 cells were grown in M9 minimal media supplemented with 0.1% casamino acids. Sixteen combinations of sodium citrate (0 mM, 0.25 mM, 0.5 mM, or 0.75 mM) and sodium pyruvate (0%, 0.1%, 0.2%, 0.4%) were added, representing all possible combinations of the three concentrations tested for each chemical. Three to six replicate cultures were grown for each pyruvate/citrate combination. Cells were grown at 37°C to a density of 10<sup>8</sup> cells/ml as measured by absorbance at 600 nm. Two ml samples of each replicate culture were stabilized in 4 ml of Qiagen RNAprotect reagent. RNA was prepared using Qiagen RNeasy kits. Reverse transcription of 1.5 µg total RNA was performed with 10 units/µL Superscript III Reverse

Transcriptase (Invitrogen) using 2.5 mM random hexamers in a total volume of 20  $\mu$ L, according to the manufacturer's instructions.

Quantitative PCR primers for the experimental fecA transcript, positive control aceE transcript, and the normalization transcripts rrlG and rrnA were designed using Primer Express Software v2.0 (Applied Biosystems). Primer specificity was confirmed with gel electrophoresis. PCR reactions were prepared using 2  $\mu$ L cDNA in a total volume of 14  $\mu$ L containing 300 nM of each primer and 7  $\mu$ L ABI Sybr Green Master Mix. Triplicate PCR reactions were performed and averaged for each of the biological replicates. Reactions were run in an ABI 7900HT.

Crossing-point threshold (Ct) and real-time fluorescence data were obtained using the ABI Prism Sequence Detection Software v2.0. Default software parameters were used except for adjustments made to the pre-exponential phase baseline used to calculate Ct for the higher abundance RNAs. Expression levels were obtained from Ct values as previously described [40].




Figure S1. The transcriptional regulatory map inferred by CLR with an estimated 80% precision.

The precision of the network is obtained by measuring the percentage of correctly inferred edges (blue lines) out of all the predicted edges for genes with known connectivity (blue lines and green lines). The green edges represent a mixture of false and novel predictions, making 80% an underestimate. The red edges are to genes without a previously identified regulator or from regulators without a previously known target. Transcription factor nodes are colored light gray.




Figure S2. Transcription factor recall

Transcription factors, with at least two inferred interactions (blue bar), have high recall (47% on average) of the their known targets (green bar –vs- red bar); this suggests that when the transcription factors in the compendium are perturbed by the appropriate condition, then much of that transcription factor's regulon is correctly identified.




Figure S3. Motifs detected for four of the transcription factors with five or more target operons.

- (A) The canonical LexA regulatory motif was detected in the promoters of 8 out of the 13 genes inferred to be LexA targets.
- (B) The canonical Lrp regulatory motif was also detected with high significance.
- (C) A novel motif was found for YnaE, a transcription factor that may play a role in the regulation of a prophage or DNA repair.
- (D) YmfN, another prophage-related transcription factor with no known regulatory targets, had a strong motif conserved in all of its predicted targets.




Figure S4. Estimating the distribution of mutual information.

The distribution of mutual information for both genes of a potential regulatory interaction is used to estimate the significance of mutual information. The distribution of mutual information for one gene lexA illustrates different types of fit. Normal fit, while not the best approximation to the empirical distribution, penalizes the distal network neighborhood.

# **Supplementary Figures**




Figure S5. Examples of typical co-variation in expression between a transcription factor and its target gene.

(A) Two key players in the SOS response, RecA and its regulatory protein LexA, are both highly expressed in the presence of a DNA damaging agent regardless of the laboratory or experimenter running the microarray. The colors for each point in (A) and (B) correspond to the experimenter. For data from other laboratories, the first author of the associated publication was used. For data from our laboratories, the experimenter name is italicized.

(B) Two genes involved in arabinose metabolism, *araA* and its regulator AraC, behave as a switch that is ON when arabinose is present in the media and OFF otherwise.




Figure S6. Lrp expression in the compendium

- (A) Confounding experiments and uneven sampling can lead to false correlations (inset) that network inference algorithms aim to eliminate. Addition of the correct condition (in this case, expression profiles on minimal media) clears the relationship.
- (B) The relationship between the Lrp transcription factor and its known target *serA* becomes more pronounced upon addition of the minimal media expression profiles in which both genes are highly active.




Figure S7. Algorithm modifications

- (A) Comparison of multivariate methods. Linear regression networks allow cycles, which provided a performance boost, compared with Bayesian networks. A regression network computed using RMA data only does not perform as well as a network computed from the consensus (average) of four normalization methods (RMA, gcRMA, dChip, and MAS5.0). Random networks represent random guessing of interactions.
- (B) The relevance networks algorithm was applied by computing pairwise similarity using mutual information, normalized mutual information, correlation, and by assigning to each gene in an operon the maximum correlation of all genes in the operon. Using correlation as a scoring metric produced the top performing relevance network algorithm.
- (C) The original ARACNe algorithm and modified versions of the algorithm were applied. The best performing version of ARACNe employed a probabilistic Data Processing Inequality to prune interactions combined with a spline-based mutual information estimator. Using probabilistic ARACNe, we computed a network using RMA data only, and a network computed from the consensus (average) of four normalization methods. The original ARACNe algorithm uses a discrete mutual information estimator and the standard DPI pruning approach. The spline

ARACNe is the same as the original ARACNe, but employs a spline-based mutual information estimator.

(D) The CLR algorithm was applied by computing pairwise similarity using mutual information, normalized mutual information, correlation, and by assigning to each gene in an operon the median or maximum correlation of all genes in the operon. CLR performs better with mutual information than correlation. Prior knowledge of operons improves performance when it is available. The Roulston method is not the CLR algorithm, but is provided for comparison. It computes a background correction using an analytical procedure [11].




Figure S8. Distribution of out-degree for networks inferred by different algorithms

All tested algorithms infer networks with an out-degree that is approximately scale-free. The linear regression and CLR methods produced networks with the largest hubs.




Figure S9. Combinatorial regulation observed in the *E. coli* compendium.

- (A) Combinatorial regulations can be classified by discretizing the expression levels of the relevant transcription factors and genes into on (T) and off (F) states. In this example, two transcription factors, (TF1) and (TF2), regulate their target gene with AND-like logic.
- (B) Many of the cases where one gene is regulated by multiple transcription factors involve two transcription factors in the same operon, which eliminates the ability to see either transcription factor expressed independently of the other. This case is difficult to classify as combinatorial regulation.
- (C) Novel interactions were predicted between CspA and CspG, two transcription factors involved in cold shock, and the target gene ddg, whose expression values are represented as

color changes.

(D) The expression profiles for the three cold shock genes strongly suggest an AND-like regulation, but there are no data for the case of high *cspG* expression with low *cspA* expression, thus preventing the conclusive determination of this promoter's combinatorial logic program.

Table S1. Functional enrichment of YmfN targets.

Functional category	Target Genes	p-value
prophage genes and phage related functions	ymfR, ymfO, ymfM, ymfL, intE	0.0001
Extrachromosomal	ymfR, ymfO, ymfM, ymfL, intE	0.0004
DNA repair	recN, dinD	0.0029
response to DNA damage stimulus	recN, dinD	0.0029
response to endogenous stimulus	recN, dinD	0.0029
response to stress	recN, dinD	0.0081
DNA related	recN, dinD	0.01
response to stimulus	recN, dinD	0.0236
DNA metabolism	recN, dinD	0.0251

 $Table \ S2. \ Functional \ enrichment \ of \ YnaE \ targets.$ 

Functional category	Target Genes	p-value
response to temperature stimulus	cspI, cspG	0.0004
response to abiotic stimulus	cspI,cspG	0.002
response to stimulus	cspI,cspG	0.0106

Table S3. z-scores of motifs for transcription factors in the 60% precision network with  $\geq$  5 predicted operon targets.

			Motif rank	95 one-sided significa	,
Regulator	# of operons	z- score	(if motif is known)	Known motif source	Possible confounding regulator (match rank)
alpA_b2624_at	5	3.39	, , , , , , , , , , , , , , , , , , ,		,
araC b0064 at	6	1.64	1	DPInteract	
arsR_b3501_at	16	2.78			
b0373_s_at	6	5.01			
b1422_at	5	0.85			
b2531 at	5	4.12			
bolA_b0435_at	5	1.14			
celD b1735 at	8	1.45			
cspB_b1557_at	5	0.45			
cspG_b0990_at	8	2.06			
cspI_b1552_at	6	0.27			
dnaA_b3702_at	11	0.32	33	DPInteract	
fecI b4293 at	7	6.21			Fur(1
fis_b3261_at	5	2.44	3	DPInteract	1(
flhC_b1891_at	19	4.05	3	Regulon	
flhD_b1892_at	18	4.80	3	Regulon	
fliA_b1922_at	20	4.89	18	PRODORIC	FlhDC(3
fnr_b1334_at	9	2.28	13	PRODORIC	
frvR b3897 at	5	0.41	15	THODOING	
fucR_b2805_at	7	-0.36			
gcvR b2479 at	5	1.28			GcvA(6
glcC_b2980_at	9	0.62			3011(0
htgA_b0012_at	8	0.46			
hycA_b2725_at	7	2.50			
leuO_b0076_at	8	3.47			
lexA_b4043_at	13	9.39	1	DPInteract	
lldR_b3604_at	5	-0.38	1	Di interact	
lrp_b0889_at	27	4.63	15	DPInteract	ArgR(1
mhpR_b0346_at	12	5.52	13	Di interact	7.118.11(1
nadR_b4390_at	6	2.17			
nlpA_b3661_at	31	5.24			purR(1
nlpC_b1708_at	9	2.21			lexA(1
nlpD_b2742_at	8	2.01			icari(i
osmE_b1739_at	33	4.16			
phnF b4102 at	7	3.10			
rhaR_b3906_at	9	0.09	41	Regulon	RhaS(3
rhaS_b3905_at	12	3.85	7	DPInteract	Kilab(S
rpoN_b3202_at	6	0.13	16	PRODORIC	RpoH(4
rstA_b1608_at	5	0.48	10	rkobolde	Rport
tdcR_b3119_at	8	0.60			
ybaQ_b0483_at	6	1.66			
ycjC_b1299_at	5	1.00			
ydaK_b1339_at	7	0.18			
	5	-0.59			
ydaR_b1356_at	11	-0.39 -0.81			
yebK_b1853_at					C-:E(1
yfeC_b2398_at	5	-0.59			CaiF(

Table S4. The clustered microarrays of the *E. coli* compendium.

TP in the Reference column indicates expression profiles contributed by this paper.

Clust	er Chip name	Experiment description	Reference
1	dinIU_N0025_r1	din I upregulation, amp 50ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD $\sim$ 0.3	TP
1	lucU_N0000_r1	luc upregulation, 0.000 ug/ml norfloxacin	TP
1	lucU_N0000_r2	luc upregulation, 0.000 ug/ml norfloxacin	TP
1	lucU_N0000_r3	luc upregulation, 0.000 ug/ml norfloxacin	TP
2	dinIU_N0025_r2	dinI upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD ~0.3	TP
2	dinIU_N0025_r3	dinI upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD ~0.3	TP
2	dinPU_N0025_r1	dinP upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD $\sim\!\!0.3$	TP
2	dinPU_N0025_r2	dinP upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD $\sim\!\!0.3$	TP
2	dinPU_N0025_r3	dinP upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD $\sim\!\!0.3$	TP
2	lexAU_N0025_r1	lexA upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD ${\sim}0.3$	TP
2	lexAU_N0025_r2	lexA upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD ${\sim}0.3$	TP
2	lexAU_N0025_r3	lexA upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD $\sim\!\!0.3$	TP
2	lonU_N0025_r1	lon upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD ~0.3	TP
2	lonU_N0025_r2	Lon upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD ~0.3	TP
2	lonU_N0025_r3	lon upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD ~0.3	TP
2	lucU_N0025_r1	luc upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD ~0.3	TP
2	lucU_N0025_r2	luc upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD ~0.3	TP
2	lucU_N0025_r3	luc upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD ~0.3	TP
2	recAU_N0025_r1	recA upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD ~0.3	TP
2	recAU_N0025_r2	recA upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD ~0.3	TP
2	recAU_N0025_r3	recA upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD ~0.3	TP
2	ruvAU_N0025_r1	ruvA upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD ~0.3	TP
2	ruvAU_N0025_r2	ruvA upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD ~0.3	TP
2	ruvAU_N0025_r3	ruvA upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD ~0.3	TP
2	sulAU_N0025_r1	sulA upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD ~0.3	TP
2	sulAU_N0025_r2	sulA upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD	TP
2	sulAU_N0025_r3	~0.3 sulA upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD	TP
2	umuDU_N0025_r1	$\sim\!\!0.3$ umuD upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD $\sim\!\!0.3$	TP

2	umuDU_N0025_r2	umuD upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD $\sim$ 0.3	TP
2	umuDU_N0025_r3	umuD upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD ~0.3	TP
2	uvrAU_N0025_r1	uvrA upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD ~0.3	TP
2	uvrAU_N0025_r2	uvrA upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD ~0.3	TP
2	uvrAU_N0025_r3	uvrA upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD ~0.3	TP
3	dnaAU_N0075_r1	dnaA upregulation, 0.075 ug/ml norfloxacin	TP
3	gyrAU_N0075_r1	gyrA upregulation, 0.075 ug/mL norfloxacin	TP
3	gyrI U N0075 r2	gyrI upregulation, 0.075 ug/mL norfloxacin	TP
3	minD U N0075 r1	minD upregulation, 0.075 ug/mL norfloxacin	TP
3	murIU_N0075_r1	murI upregulation, 0.075 ug/mL norfloxacin	TP
3	rstB U N0075 r1	rstB upregulation, 0.075 ug/mL norfloxacin	TP
3	uspA U N0075 r1	uspA upregulation, 0.075 ug/mL norfloxacin	TP
4	dnaA U N0075 r2	dnaA upregulation, 0.075 ug/ml norfloxacin	TP
4	gyrI U N0075 r1	gyrI upregulation, 0.075 ug/mL norfloxacin	TP
4	menB U N0075 r1	menB upregulation, 0.075 ug/mL norfloxacin	TP
5	dnaN U N0075 r1	dnaN upregulation, 0.075 ug/ml norfloxacin	TP
5	dnaT U N0075 r1	dnaT upregulation, 0.075 ug/ml norfloxacin	TP
5	sbcB U N0075 r1	sbcB upregulation, 0.075 ug/mL norfloxacin	TP
6	dnaN U N0075 r2	dnaN upregulation, 0.075 ug/ml norfloxacin	TP
6	dnaT U N0075 r2	dnaT upregulation, 0.075 ug/ml norfloxacin	TP
6	hscA_U_N0075_r2	hscA upregulation, 0.075 ug/mL norfloxacin	TP
6	minEU_N0075_r2	minE upregulation, 0.075 ug/mL norfloxacin	TP
6	murI U N0075 r2	murI upregulation, 0.075 ug/mL norfloxacin	TP
6	sbcB U N0075 r2	sbcB upregulation, 0.075 ug/mL norfloxacin	TP
7	emrR U N0075 r1	emrR upregulation, 0.075 ug/ml norfloxacin	TP
7	holD_U_N0075_r1	holD upregulation, 0.075 ug/mL norfloxacin	TP
7	hscAU_N0075_r1	hscA upregulation, 0.075 ug/mL norfloxacin	TP
7	IHFU_N0075_r1	IHF upregulation, 0.075 ug/mL norfloxacin	TP
7	minE U N0075 r1	minE upregulation, 0.075 ug/mL norfloxacin	TP
7	nrdAU_N0075_r1	nrdA upregulation, 0.075 ug/mL norfloxacin	TP
7	nrdB_U_N0075_r1	nrdB upregulation, 0.075 ug/mL norfloxacin	TP
8	emrRU_N0075_r3	emrR upregulation, 0.075 ug/ml norfloxacin	TP
8	hlpA_U_N0075_r2	hlpA upregulation, 0.075 ug/mL norfloxacin	TP
8	holD_U_N0075_r2	holD upregulation, 0.075 ug/mL norfloxacin	TP
8	hscA_U_N0075_r3	hscA upregulation, 0.075 ug/mL norfloxacin	TP
8	IHFU_N0075_r3	IHF upregulation, 0.075 ug/mL norfloxacin	TP
8	nrdAU_N0075_r3	nrdA upregulation, 0.075 ug/mL norfloxacin	TP
8	nrdB U N0075 r3	nrdB upregulation, 0.075 ug/mL norfloxacin	TP
8	ruvCU_N0075_r1	ruvC upregulation, 0.075 ug/mL norfloxacin	TP
9	folAU_N0075_r2	folA upregulation, 0.075 ug/ml norfloxacin	TP
9	menCU_N0075_r2	menC upregulation, 0.075 ug/mL norfloxacin	TP
10	galFU_N0075_r1	galF upregulation, 0.075 ug/ml norfloxacin	TP
10	hlpA_U_N0075_r1	hlpA upregulation, 0.075 ug/mL norfloxacin	TP
10	menCU_N0075_r3	menC upregulation, 0.075 ug/mL norfloxacin	TP
11	galFU_N0075_r2	galF upregulation, 0.075 ug/ml norfloxacin	TP
11	nupCU_N0075_r2	nupC upregulation, 0.075 ug/mL norfloxacin	TP
		<u> </u>	

12	gcvRU_N0075_r1	gcvR upregulation, 0.075 ug/mL norfloxacin	TP
12	gyrIU_N0075_r3	gyrl upregulation, 0.075 ug/mL norfloxacin	TP
12	holDU_N0075_r3	holD upregulation, 0.075 ug/mL norfloxacin	TP
12	minDU_N0075_r3	minD upregulation, 0.075 ug/mL norfloxacin	TP
12	murIU_N0075_r3	murI upregulation, 0.075 ug/mL norfloxacin	TP
12	rimIU_N0075_r1	rimI upregulation, 0.075 ug/mL norfloxacin	TP
12	rimIU_N0075_r3	rimI upregulation, 0.075 ug/mL norfloxacin	TP
12	rstBU_N0075_r3	rstB upregulation, 0.075 ug/mL norfloxacin	TP
12	ruvCU_N0075_r3	ruvC upregulation, 0.075 ug/mL norfloxacin	TP
12	sbcBU_N0075_r3	sbcB upregulation, 0.075 ug/mL norfloxacin	TP
13	menCU_N0075_r1	menC upregulation, 0.075 ug/mL norfloxacin	TP
13	minDU_N0075_r2	minD upregulation, 0.075 ug/mL norfloxacin	TP
14	yoeBU_N0075_r1	yoeB upregulation, 0.075 ug/mL norfloxacin	TP
14	yoeBU_N0075_r2	yoeB upregulation, 0.075 ug/mL norfloxacin	TP
14	yoeBU_N0075_r3	yoeB upregulation, 0.075 ug/mL norfloxacin	TP
15	nupCU_N0075_r3	nupC upregulation, 0.075 ug/mL norfloxacin	TP
16	mazFU_N0025_r1	mazF_chpA upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD ~0.3	TP
16	mazFU_N0025_r2	mazF_chpA upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD ~0.3	TP
16	mazFU_N0025_r3	mazF_chpA upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD ~0.3	TP
16	relEU_N0025_r1	relE upregulation, amp 50 ug/ml, $0.0125\%$ arabinose, $0.025$ ug/ml norfloxacin OD $\sim 0.3$	TP
16	relEU_N0025_r2	relE upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD $\sim\!\!0.3$	TP
16	relEU_N0025_r3	relE upregulation, amp 50 ug/ml, 0.0125% arabinose, 0.025 ug/ml norfloxacin OD ~0.3	TP
17	WT_N0000_r1	wild-type cells without norfloxacin	TP
17	WT_N0000_r2	wild-type cells without norfloxacin	TP
17	WT_N0025_r1	wild-type cells with 0.025 ug/ml norfloxacin	TP
17	WT_N0025_r2	wild-type cells with 0.025 ug/ml norfloxacin	TP
17	WT_N0050_r1	wild-type cells with 0.050 ug/ml norfloxacin	TP
17	WT_N0050_r2	wild-type cells with 0.050 ug/ml norfloxacin	TP
18	WT_N0075_r1	wild-type cells with 0.075 ug/ml norfloxacin	TP
18	WT_N0075_r2	wild-type cells with 0.075 ug/ml norfloxacin	TP
19	recA_D_N0000_r1	recA deletion 0 ug/ml norfloxacin	TP
19	recA_D_N0000_r2	recA deletion 0 ug/ml norfloxacin	TP
19	recA_D_N0050_r1	recA deletion 0.05 ug/ml norfloxacin	TP
19	recA_D_N0050_r2	recA deletion 0.05 ug/ml norfloxacin	TP
19	recA_D_N1000_r1	recA deletion 1.0 ug/ml norfloxacin	TP
19	recA_D_N1000_r2	recA deletion 1.0 ug/ml norfloxacin	TP
19	WT_D_N1000_r1	wild-type 1.0 ug/ml norfloxacin	TP
19	WT_D_N1000_r2	wild-type 1.0 ug/ml norfloxacin	TP
20	luc2_U_N0025_r1	luciferase 0.025 ug/ml norfloxacin	TP
20	luc2_U_N0000_r1	luciferase no drug	TP
21	luc2_U_N0025_r2	luciferase 0.025 ug/ml norfloxacin	TP
21	luc2_U_N0000_r2	luciferase no drug	TP
22	T0_N0025_r1	cells prior to treatment by norfloxacin	TP
22	T0_N0025_r2	cells prior to treatment by norfloxacin	TP
22	T0_N0025_r3	cells prior to treatment by norfloxacin	TP
23	T12_N0025_r1	cells 12 min after treatment by norfloxacin	TP

```
23
       T12 N0025 r2
                              cells 12 min after treatment by norfloxacin
                                                                                                               TP
23
       T12 N0025 r3
                              cells 12 min after treatment by norfloxacin
                                                                                                               TP
23
                              cells 24 min after treatment by norfloxacin
       T24 N0025 r1
                                                                                                               TP
23
                              cells 24 min after treatment by norfloxacin
       T24 N0025 r2
                                                                                                               TP
23
       T24 N0025 r3
                              cells 24 min after treatment by norfloxacin
                                                                                                               TP
23
                              cells 36 min after treatment by norfloxacin
       T36 N0025 r1
                                                                                                               TP
23
       T36 N0025 r2
                              cells 36 min after treatment by norfloxacin
                                                                                                               TP
23
       T36 N0025 r3
                              cells 36 min after treatment by norfloxacin
                                                                                                               TP
23
       T48 N0025 r1
                              cells 48 min after treatment by norfloxacin
                                                                                                               TP
23
                              cells 48 min after treatment by norfloxacin
                                                                                                               TP
       T48 N0025 r2
23
       T48 N0025 r3
                              cells 48 min after treatment by norfloxacin
                                                                                                               TP
23
                              cells 60 min after treatment by norfloxacin
                                                                                                               TP
       T60_N0025_r1
23
       T60 N0025 r2
                              cells 60 min after treatment by norfloxacin
                                                                                                               TP
23
       T60 N0025 r3
                              cells 60 min after treatment by norfloxacin
                                                                                                               TP
24
       T24 N0000 r1
                              untreated cells after 24 min
                                                                                                               TP
                              untreated cells after 24 min
24
       T24 N0000 r2
                                                                                                               TP
24
       T24 N0000 r3
                              untreated cells after 24 min
                                                                                                               TP
24
       T60 N0000 r1
                              untreated cells after 60 min
                                                                                                               TP
       T60_N0000 r2
24
                              untreated cells after 60 min
                                                                                                               TP
24
       T60 N0000 r3
                              untreated cells after 60 min
                                                                                                               TP
25
                              E.coli K12 with ccdB upregulation 0 minutes after induction
       ccdB K12 0 r1
                                                                                                               TP
25
       lacZ K12 0 r1
                              E.coli K12 with lacZ upregulation 0 minutes after induction
                                                                                                               TP
                              E.coli K12 with ccdB upregulation 30 minutes after induction
26
       ccdB K12 30 r1
                                                                                                               TP
26
       ccdB K12 60 r1
                              E.coli K12 with ccdB upregulation 60 minutes after induction
                                                                                                               TP
26
       lacZ K12 30 r1
                              E.coli K12 with lacZ upregulation 30 minutes after induction
                                                                                                               TP
26
       lacZ_K12_60_r1
                              E.coli K12 with lacZ upregulation 60 minutes after induction
                                                                                                               TP
27
       ccdB K12 90 r1
                              E.coli K12 with ccdB upregulation 90 minutes after induction
                                                                                                               TP
27
       ccdB K12 120 r1
                              E.coli K12 with ccdB upregulation 120 minutes after induction
                                                                                                               TP
28
       lacZ K12 90 r1
                              E.coli K12 with lacZ upregulation 90 minutes after induction
                                                                                                               TP
28
       lacZ K12 120 r1
                              E.coli K12 with lacZ upregulation 120 minutes after induction
                                                                                                               TP
29
       lacZ MG1063 0 r1
                              E.coli MG1063 (recA56 = recA-) with lacZ upregulation 0 minutes after induction
                                                                                                               TP
29
                              E.coli MG1063 (recA56 = recA-) with lacZ upregulation 30 minutes after induction TP
       lacZ MG1063 30 r1
                              E.coli MG1063 (recA56 = recA-) with lacZ upregulation 60 minutes after induction
29
       lacZ MG1063 60 r1
29
       lacZ MG1063 90 r1
                              E.coli MG1063 (recA56 = recA-) with lacZ upregulation 90 minutes after induction
29
       ccdB MG1063 0 r1
                              E.coli MG1063 (recA56 = recA-) with ccdB upregulation 0 minutes after induction
29
                              E.coli MG1063 (recA56 = recA-) with ccdB upregulation 30 minutes after induction TP
       ccdB MG1063 30 r1
29
                              E.coli MG1063 (recA56 = recA-) with ccdB upregulation 60 minutes after induction TP
       ccdB MG1063 60 r1
29
                              E.coli MG1063 (recA56 = recA-) with lacZ upregulation 0 minutes after induction
       lacZ MG1063 0 r2
                                                                                                               TP
29
       lacZ MG1063 30 r2
                              E.coli MG1063 (recA56 = recA-) with lacZ upregulation 30 minutes after induction TP
29
       lacZ MG1063 60 r2
                              E.coli MG1063 (recA56 = recA-) with lacZ upregulation 60 minutes after induction
29
       lacZ MG1063 90 r2
                              E.coli MG1063 (recA56 = recA-) with lacZ upregulation 90 minutes after induction
29
       lacZ MG1063 120 r1 E.coli MG1063 (recA56 = recA-) with lacZ upregulation 120 minutes after induction TP
29
                              E.coli MG1063 (recA56 = recA-) with ccdB upregulation 0 minutes after induction
       ccdB MG1063 0 r2
29
       ccdB MG1063 30 r2 E.coli MG1063 (recA56 = recA-) with ccdB upregulation 30 minutes after induction TP
29
       ccdB MG1063 60 r2 E.coli MG1063 (recA56 = recA-) with ccdB upregulation 60 minutes after induction TP
30
       ccdB MG1063 90 r1 E.coli MG1063 (recA56 = recA-) with ccdB upregulation 90 minutes after induction TP
       ccdB MG1063 90 r2 E.coli MG1063 (recA56 = recA-) with ccdB upregulation 90 minutes after induction TP
30
30
       ccdB MG1063 120 r1 E.coli MG1063 (recA56 = recA-) with ccdB upregulation 120 minutes after induction TP
31
       lacZ W1863 0 r1
                              E.coli W1863 wt lambda- with lacZ upregulation 0 minutes after induction
                                                                                                               TP
                              strain K12 in LB pH adjusted to 5 with KOH and buffered with HOMOPIPES
31
       ph5 r1
                                                                                                               [1]
```

31	ph5_r2	strain K12 in LB pH adjusted to 5 with KOH and buffered with HOMOPIPES	[1]
31	ph5_r3	strain K12 in LB pH adjusted to 5 with KOH and buffered with HOMOPIPES	[1]
31	ph5_r4	strain K12 in LB pH adjusted to 5 with KOH and buffered with HOMOPIPES	[1]
31	ph5_r5	strain K12 in LB pH adjusted to 5 with KOH and buffered with HOMOPIPES	[1]
31	ph7_r1	strain K12 in LB pH adjusted to 7 with KOH and buffered with HOMOPIPES	[1]
31	ph7_r2	strain K12 in LB pH adjusted to 7 with KOH and buffered with HOMOPIPES	[1]
31	ph7_r3	strain K12 in LB pH adjusted to 7 with KOH and buffered with HOMOPIPES	[1]
31	ph7_r4	strain K12 in LB pH adjusted to 7 with KOH and buffered with HOMOPIPES	[1]
31	ph7_r5	strain K12 in LB pH adjusted to 7 with KOH and buffered with HOMOPIPES	[1]
31	ph8.7_r1	strain K12 in LB pH adjusted to 8.7 with KOH and buffered with HOMOPIPES	[1]
31	ph8.7_r2	strain K12 in LB pH adjusted to 8.7 with KOH and buffered with HOMOPIPES	[1]
31	ph8.7_r3	strain K12 in LB pH adjusted to 8.7 with KOH and buffered with HOMOPIPES	[1]
31	ph8.7_r4	strain K12 in LB pH adjusted to 8.7 with KOH and buffered with HOMOPIPES	[1]
31	ph8.7_r5	strain K12 in LB pH adjusted to 8.7 with KOH and buffered with HOMOPIPES	[1]
32	lacZ_W1863_30_r1	E.coli W1863 wt lambda- with lacZ upregulation 30 minutes after induction	TP
32	lacZ_W1863_60_r1	E.coli W1863 wt lambda- with lacZ upregulation 60 minutes after induction	TP
32	ccdB_W1863_0_r1	E.coli W1863 wt lambda- with ccdB upregulation 0 minutes after induction	TP
32	ccdB_W1863_30_r1	E.coli W1863 wt lambda- with ccdB upregulation 30 minutes after induction	TP
33	lacZ_W1863_90_r1	E.coli W1863 wt lambda- with lacZ upregulation 90 minutes after induction	TP
33	ccdB_W1863_60_r1	E.coli W1863 wt lambda- with ccdB upregulation 60 minutes after induction	TP
33	ccdB_W1863_90_r1	E.coli W1863 wt lambda- with ccdB upregulation 90 minutes after induction	TP
34	appY_KO9_r1	aerobic growth of appY knock-out strain on M9 media with glucose	[2]
34	appY_KO9_r2	aerobic growth of appY knock-out strain on M9 media with glucose	S
34	arcA_KO9_r1	aerobic growth of arcA knock-out strain on M9 media with glucose	[2]
34	arcA_KO9_r2	aerobic growth of arcA knock-out strain on M9 media with glucose	[2]
34	arcA_KO9_r3	aerobic growth of arcA knock-out strain on M9 media with glucose	[2]
34	arcAfnr_KO9_r1	aerobic growth of arcA/fnr double knock-out strain on M9 media with glucose	[2]
34	arcAfnr_KO9_r2	aerobic growth of arcA/fnr double knock-out strain on M9 media with glucose	[2]
34	arcAfnr_KO9_r3	aerobic growth of arcA/fnr double knock-out strain on M9 media with glucose	[2]
34	fnr_KO9_r1	aerobic growth of fnr knock-out strain on M9 media with glucose	[2]
34	fnr_KO9_r2	aerobic growth of fnr knock-out strain on M9 media with glucose	[2]
34	fnr_KO9_r3	aerobic growth of fnr knock-out strain on M9 media with glucose	[2]
34	oxyR_KO9_r1	aerobic growth of oxyR knock-out strain on M9 media with glucose	[2]
34	oxyR_KO9_r2	aerobic growth of oxyR knock-out strain on M9 media with glucose	[2]
34	oxyR_KO9_r3	aerobic growth of oxyR knock-out strain on M9 media with glucose	[2]
34	soxS_KO9_r1	aerobic growth of soxS knock-out strain on M9 media with glucose	[2]
34	soxS_KO9_r2	aerobic growth of soxS knock-out strain on M9 media with glucose	[2]
34	soxS_KO9_r3	aerobic growth of soxS knock-out strain on M9 media with glucose	[2]
34	WT_O9_r1	aerobic aerobic growth of wild-type strain on M9 media with glucose	[2]
34	WT_O9_r2	aerobic aerobic growth of wild-type strain on M9 media with glucose	[2]
34	WT_O9_r3	aerobic aerobic growth of wild-type strain on M9 media with glucose	[2]
34	arcA_KN9_r1	anaerobic growth of arcA knock-out strain on M9 media with glucose	[2]
34	arcA_KN9_r2	anaerobic growth of arcA knock-out strain on M9 media with glucose	[2]
34	arcA_KN9_r3	anaerobic growth of arcA knock-out strain on M9 media with glucose	[2]
34	arcAfnr_KN9_r1	anaerobic growth of arcA/fnr double knock-out strain on M9 media with glucose	[2]
34	arcAfnr_KN9_r2	anaerobic growth of arcA/fnr double knock-out strain on M9 media with glucose	[2]
34	arcAfnr_KN9_r3	anaerobic growth of arcA/fnr double knock-out strain on M9 media with glucose	[2]
35	appY_KO9_r3	aerobic growth of appY knock-out strain on M9 media with glucose	[2]
35	fnr_KN9_r1	anaerobic growth of fnr knock-out strain on M9 media with glucose	[2]
35	cybr_N_stat_r1	BW30270 stationary phase, anaerobic on MOPS minimal media with glucose	[3]

35	cybr_N_stat_r2	BW30270 stationary phase, anaerobic on MOPS minimal media with glucose	[3]
36	appY_KN9_r1	anaerobic growth of appY knock-out strain on M9 media with glucose	[2]
36	appY_KN9_r2	anaerobic growth of appY knock-out strain on M9 media with glucose	[2]
36	appY_KN9_r3	anaerobic growth of appY knock-out strain on M9 media with glucose	[2]
36	fnr_KN9_r2	anaerobic growth of fnr knock-out strain on M9 media with glucose	[2]
36	fnr_KN9_r3	anaerobic growth of fnr knock-out strain on M9 media with glucose	[2]
36	oxyR_KN9_r1	anaerobic growth of oxyR knock-out strain on M9 media with glucose	[2]
36	oxyR_KN9_r2	anaerobic growth of oxyR knock-out strain on M9 media with glucose	[2]
36	oxyR_KN9_r3	anaerobic growth of oxyR knock-out strain on M9 media with glucose	[2]
36	soxS_KN9_r1	anaerobic growth of soxS knock-out strain on M9 media with glucose	[2]
36	soxS_KN9_r2	anaerobic growth of soxS knock-out strain on M9 media with glucose	[2]
36	soxS_KN9_r3	anaerobic growth of soxS knock-out strain on M9 media with glucose	[2]
36	WT_N9_r1	anaerobic growth of wild-type strain on M9 media with glucose	[2]
36	WT N9 r2	anaerobic growth of wild-type strain on M9 media with glucose	[2]
36	WT N9 r3	anaerobic growth of wild-type strain on M9 media with glucose	[2]
36	WT N9 r4	anaerobic growth of wild-type strain on M9 media with glucose	[2]
37	yebF U N0075 r1	yebF upregulation, 0.075 ug/ml norfloxacin	TP
37	yebFU_N0075_r3	yebF upregulation, 0.075 ug/ml norfloxacin	TP
38	yebFU_N0075_r2	yebF upregulation, 0.075 ug/ml norfloxacin	TP
38	damU_N0075_r2	dam upregulation, 0.075 ug/ml norfloxacin	TP
39	WT_OPG_r1	aerobic growth wild-type cells OD 0.2 on MOPS media with glucose	[4]
39	ast_pBADsup2_r1	MG1655 OD 0.2 on MOPS media with arabinose controlled induction of an amber suppressor tRNA	[5]
39	ast_pBADsup2_r2	MG1655 OD 0.2 on MOPS media with arabinose controlled induction of an amber suppressor tRNA	[5]
39	ast_pBADsup2_r3	MG1655 OD 0.2 on MOPS media with arabinose controlled induction of an amber suppressor tRNA	[5]
39	ast pBAD18 r1	MG1655 OD 0.2 on MOPS media with empty pBAD18 vector	[5]
39	ast pBAD18 r2	MG1655 OD 0.2 on MOPS media with empty pBAD18 vector	[5]
39	ast_pBAD18_r3	MG1655 OD 0.2 on MOPS media with empty pBAD18 vector	[5]
39	cybr_O_r1	MG1655 log phase, aerobic on MOPS minimal media with glucose	[3]
39	cybr O r2	MG1655 log phase, aerobic on MOPS minimal media with glucose	[3]
39	cybr_O_log_r1	BW30270 log phase, aerobic on MOPS minimal media with glucose	[3]
39	cybr O log r2	BW30270 log phase, aerobic on MOPS minimal media with glucose	[3]
40	lucU_N0075_r1	luc upregulation, 0.075 ug/ml norfloxacin	TP
40	lucU_N0075_r3	luc upregulation, 0.075 ug/ml norfloxacin	TP
41	lucU_N0075_r2	luc upregulation, 0.075 ug/ml norfloxacin	TP
41	zipAU_N0075_r2	zipA upregulation, 0.075 ug/ml norfloxacin	TP
41	zipAU_N0075_r3	zipA upregulation, 0.075 ug/ml norfloxacin	TP
41	cspFU_N0075_r1	cspF upregulation, 0.075 ug/ml norfloxacin	TP
41	cspFU_N0075_r2	cspF upregulation, 0.075 ug/ml norfloxacin	TP
41	damU_N0075_r1	dam upregulation, 0.075 ug/ml norfloxacin	TP
41	damU_N0075_r3	dam upregulation, 0.075 ug/ml norfloxacin	TP
41	fisU_N0075_r2	fis upregulation, 0.075 ug/ml norfloxacin	TP
41	gcvRU_N0075_r2	gcvR upregulation, 0.075 ug/ml norfloxacin	TP
41	nrdAU_N0075_r2	nrdA upregulation, 0.075 ug/ml norfloxacin	TP
41	ruvCU_N0075_r2	ruvC upregulation, 0.075 ug/ml norfloxacin	TP
42	WT_OPG_r2	aerobic growth wild-type cells OD 0.2 on MOPS media with glucose	[4]
42	WT_OPG_r3	aerobic growth wild-type cells OD 0.2 on MOPS media with glucose	[4]
42	WT_OPG_r4	aerobic growth wild-type cells OD 0.2 on MOPS media with glucose	[4]
42	WT_OPG_r5	aerobic growth wild-type cells OD 0.2 on MOPS media with glucose	[4]

42	WT_OPG1_r1	aerobic growth wild-type late log phase 90min MOPS media with glucose	[4]
42	WT_OPG1_r2	aerobic growth wild-type late log phase 90 min MOPS media with glucose	[4]
42	WT_OPG1_r3	aerobic growth wild-type late log phase 90 min MOPS media with glucose	[4]
42	WT_OPGA_r1	aerobic growth wild-type log phase MOPS media with glucose 10 min acid shock pF 2	I [4]
42	WT_OPGA_r2	aerobic growth wild-type log phase MOPS media with glucose 10 min acid shock pF 2	I [4]
42	WT_OPGC1_r1	aerobic growth wild-type log phase MOPS media with glucose 10 min ciprofloxacin $20 \text{ ng/ml}$	[4]
42	WT_OPGC2_r1	aerobic growth wild-type log phase MOPS media with glucose 30 min ciprofloxacin 20 ng/ml	[4]
42	cspA_KOPG_r1	cspA::Tn5 mutant aerobic growth wild-type log phase MOPS media	[4]
42	dps_KOPG_r1	dps::Tn5 mutant aerobic growth wild-type log phase MOPS media	[4]
42	dps_KOPG_r2	dps::Tn5 mutant aerobic growth wild-type log phase MOPS media	[4]
42	dps_KOPG_r3	dps::Tn5 mutant aerobic growth wild-type log phase MOPS media	[4]
42	hupB_KOPG_r1	hupB::Tn5 mutant aerobic growth wild-type log phase MOPS media	[4]
42	fnr_DfnrAerobic_r1	MG1655 with fnr deletion OD 0.2 grown aerobically	[6]
42	fnr_DfnrAerobic_r2	MG1655 with fnr deletion OD 0.2 grown aerobically	[6]
42	fnr DfnrAerobic r3	MG1655 with fnr deletion OD 0.2 grown aerobically	[6]
43	zipAU_N0075_r1	zipA upregulation, 0.075 ug/ml norfloxacin	TP
44	WT OPA r1	aerobic growth wild-type cells OD 0.2 on MOPS media with acetate	[4]
44	WT_OPA_r2	aerobic growth wild-type cells OD 0.2 on MOPS media with acetate	[4]
44	WT_OPY_r1	aerobic growth wild-type cells OD 0.2 on MOPS media with glycerol	[4]
44	WT_OPY_r2	aerobic growth wild-type cells OD 0.2 on MOPS media with glycerol	[4]
44	WT_OPL_r1	aerobic growth wild-type cells OD 0.2 on MOPS media with proline	[4]
44	WT_OPL_r2	aerobic growth wild-type cells OD 0.2 on MOPS media with proline	[4]
44	WT OPG2 r1	aerobic growth wild-type stationary phase 135 min MOPS media with glucose	[4]
44	WT OPG2 r2	aerobic growth wild-type stationary phase 135 min MOPS media with glucose	[4]
44	csf succinate r1	aerobic growth wild-type cells OD 0.2 on MOPS media with acetate	[7]
44	csf succinate r2	aerobic growth wild-type cells OD 0.2 on MOPS media with acetate	[7]
45	WT_OPG3_r1	aerobic growth wild-type stationary phase 330 min MOPS media with glucose	[4]
45	WT_OPG3_r2	aerobic growth wild-type stationary phase 330 min MOPS media with glucose	[4]
45	WT_OPG4_r1	aerobic growth wild-type stationary phase 480 min MOPS media with glucose	[4]
45	WT OPG4 r2	aerobic growth wild-type stationary phase 480 min MOPS media with glucose	[4]
45	WT OPG5 r1	aerobic growth wild-type stationary phase 720 min MOPS media with glucose	[4]
45	WT OPG5 r2	aerobic growth wild-type stationary phase 720 min MOPS media with glucose	[4]
45	dps KOPG2 r1	dps::Tn5 mutant aerobic growth wild-type stationary phase 240 min MOPS media	[4]
45	dps_KOPG2_r2	dps::Tn5 mutant aerobic growth wild-type stationary phase 240 min MOPS media	[4]
45	dps_KOPG3_r1	dps::Tn5 mutant aerobic growth wild-type stationary phase 480 min MOPS media	[4]
45	cybr_O_stat_r1	BW30270 stationary phase, aerobic on MOPS minimal media with glucose	[3]
45	cybr O stat r2	BW30270 stationary phase, aerobic on MOPS minimal media with glucose	[3]
46	WT_OPGH_r1	aerobic growth wild-type log phase MOPS media with glucose 10min heat shock 50°C	[4]
46	crp_KOPG_r1	crp::Tn5 mutant aerobic growth wild-type log phase MOPS media	[4]
46	crp_KOPG_r2	crp::Tn5 mutant aerobic growth wild-type log phase MOPS media	[4]
46	crp_KOPG_r3	crp::Tn5 mutant aerobic growth wild-type log phase MOPS media	[4]
46	hns KOPG r1	hns::Tn5 mutant aerobic growth wild-type log phase MOPS media	[4]
46	hns_KOPG_r2	hns::Tn5 mutant aerobic growth wild-type log phase MOPS media	[4]
46	hns_KOPG_r3	hns::Tn5 mutant aerobic growth wild-type log phase MOPS media	[4]
47	MGD1_t0_r1	strain BL21 (DE3) with mussel defensin protein MGD1 on T7 controllable plasmid preinduction	[8]
47	MGD1_t30_r2	strain BL21 (DE3) with mussel defensin protein MGD1 on T7 controllable plasmid	[8]

30min postinduction with 1mM IPTG 47 pET3d_t0_r2 strain BL21 (DE3) with pET3d plasmid and no insert dna (makes 26 amino acid polypeptide) preinduction 48 MGD1_t0_r2 strain BL21 (DE3) with mussel defensin protein MGD1 on T7 controllable plasmid preinduction 48 pET3d_t0_r1 strain BL21 (DE3) with pET3d plasmid and no insert dna (makes 26 amino acid polypeptide) preinduction 48 pepAA_t0_r1 strain BL21 (DE3) with T7 controllable synthetic peptide containing least abundand E. coli amino acids preinduction 48 pepCO_t0_r1 strain BL21 (DE3) with T7 controllable synthetic peptide containing least abundand E. coli amino acids preinduction 48 pepCO_t0_r1 strain BL21 (DE3) with T7 controllable synthetic peptide containing most abundand E. coli amino acids preinduction 48 pepCO_t0_r2 strain BL21 (DE3) with T7 controllable synthetic peptide containing most abundand E. coli amino acids preinduction 48 pepCO_t30_r1 strain BL21 (DE3) with T7 controllable synthetic peptide containing most abundand E. coli amino acids 30 min postinduction with 1mM IPTG 49 b2618_U_N0075_r1 b2618 upregulation, 0.075 ug/ml norfloxacin 49 bcp_U_N0075_r1 bcp upregulation, 0.075 ug/ml norfloxacin 49 cpxR_U_N0075_r1 cpxR upregulation, 0.075 ug/ml norfloxacin 49 cpxR_U_N0075_r1 crcB upregulation, 0.075 ug/ml norfloxacin 49 crcB_U_N0075_r3 crcB upregulation, 0.075 ug/ml norfloxacin	[8] at [8] at [8] at [8] at [8] at [8] TP TP TP TP TP TP TP TP TP
polypeptide) preinduction strain BL21 (DE3) with mussel defensin protein MGD1 on T7 controllable plasmin preinduction strain BL21 (DE3) with pET3d plasmid and no insert dna (makes 26 amino acid polypeptide) preinduction strain BL21 (DE3) with T7 controllable synthetic peptide containing least abundant E. coli amino acids preinduction strain BL21 (DE3) with T7 controllable synthetic peptide containing least abundant E. coli amino acids preinduction strain BL21 (DE3) with T7 controllable synthetic peptide containing most abundant E. coli amino acids preinduction strain BL21 (DE3) with T7 controllable synthetic peptide containing most abundant E. coli amino acids preinduction strain BL21 (DE3) with T7 controllable synthetic peptide containing most abundant E. coli amino acids preinduction strain BL21 (DE3) with T7 controllable synthetic peptide containing most abundant E. coli amino acids preinduction strain BL21 (DE3) with T7 controllable synthetic peptide containing most abundant E. coli amino acids 30 min postinduction with 1mM IPTG b2618 U_N0075_r1 b2618 upregulation, 0.075 ug/ml norfloxacin bcp_U_N0075_r1 bcp upregulation, 0.075 ug/ml norfloxacin bcp_U_N0075_r1 bcp upregulation, 0.075 ug/ml norfloxacin cpxR_U_N0075_r1 cpxR upregulation, 0.075 ug/ml norfloxacin crab_U_N0075_r1 crab upregulation, 0.075 ug/ml norfloxacin crab_U_N0075_r1 crab upregulation, 0.075 ug/ml norfloxacin crab_U_N0075_r1 crab upregulation, 0.075 ug/ml norfloxacin crab_U_N0075_r3 crab upregulation, 0.075 ug/ml norfloxacin	[8] [8] [8] [8] [8] [8] [8] [8] [8] [8]
48 MGD1_t0_r2 strain BL21 (DE3) with pET3d plasmid and no insert dna (makes 26 amino acid polypeptide) preinduction 48 pepAA_t0_r1 strain BL21 (DE3) with pET3d plasmid and no insert dna (makes 26 amino acid polypeptide) preinduction 48 pepAA_t0_r1 strain BL21 (DE3) with T7 controllable synthetic peptide containing least abundant E. coli amino acids preinduction 48 pepCO_t0_r1 strain BL21 (DE3) with T7 controllable synthetic peptide containing most abundant E. coli amino acids preinduction 48 pepCO_t0_r1 strain BL21 (DE3) with T7 controllable synthetic peptide containing most abundant E. coli amino acids preinduction 48 pepCO_t30_r1 strain BL21 (DE3) with T7 controllable synthetic peptide containing most abundant E. coli amino acids preinduction 49 b2618_U_N0075_r1 b2618 upregulation, 0.075 ug/ml norfloxacin 49 b2618_U_N0075_r1 bcp upregulation, 0.075 ug/ml norfloxacin 49 bcp_U_N0075_r1 bcp upregulation, 0.075 ug/ml norfloxacin 49 cpxR_U_N0075_r1 cpxR upregulation, 0.075 ug/ml norfloxacin 49 crab_U_N0075_r1 crab upregulation, 0.075 ug/ml norfloxacin	[8]  at [8]  at [8]  at [8]  at [8]  TP  TP  TP  TP  TP  TP  TP  TP
strain BL21 (DE3) with pET3d plasmid and no insert dna (makes 26 amino acid polypeptide) preinduction  strain BL21 (DE3) with T7 controllable synthetic peptide containing least abundant E. coli amino acids preinduction  strain BL21 (DE3) with T7 controllable synthetic peptide containing least abundant E. coli amino acids preinduction  strain BL21 (DE3) with T7 controllable synthetic peptide containing most abundant E. coli amino acids preinduction  strain BL21 (DE3) with T7 controllable synthetic peptide containing most abundant E. coli amino acids preinduction  strain BL21 (DE3) with T7 controllable synthetic peptide containing most abundant E. coli amino acids preinduction  strain BL21 (DE3) with T7 controllable synthetic peptide containing most abundant E. coli amino acids 30 min postinduction with 1mM IPTG  b2618_U_N0075_r1 b2618 upregulation, 0.075 ug/ml norfloxacin  bcpU_N0075_r1 bcp upregulation, 0.075 ug/ml norfloxacin  bcpU_N0075_r1 bcp upregulation, 0.075 ug/ml norfloxacin  bcpU_N0075_r1 cpxR upregulation, 0.075 ug/ml norfloxacin  cpxR_U_N0075_r1 cpxR upregulation, 0.075 ug/ml norfloxacin  crcB_U_N0075_r1 crcB upregulation, 0.075 ug/ml norfloxacin  crcB_U_N0075_r3 crcB upregulation, 0.075 ug/ml norfloxacin  crcB_U_N0075_r3 crcB upregulation, 0.075 ug/ml norfloxacin	at [8] at [8] at [8] at [8] at [8] at [8]  TP TP TP TP TP TP TP TP
48pepAA_t0_r1strain BL21 (DE3) with T7 controllable synthetic peptide containing least abundant E. coli amino acids preinduction48pepAA_t0_r2strain BL21 (DE3) with T7 controllable synthetic peptide containing least abundant E. coli amino acids preinduction48pepCO_t0_r1strain BL21 (DE3) with T7 controllable synthetic peptide containing most abundant E. coli amino acids preinduction48pepCO_t0_r2strain BL21 (DE3) with T7 controllable synthetic peptide containing most abundant E. coli amino acids preinduction48pepCO_t30_r1strain BL21 (DE3) with T7 controllable synthetic peptide containing most abundant E. coli amino acids 30 min postinduction with 1mM IPTG49b2618_U_N0075_r1b2618 upregulation, 0.075 ug/ml norfloxacin49b2618_U_N0075_r3b2618 upregulation, 0.075 ug/ml norfloxacin49bcpU_N0075_r1bcp upregulation, 0.075 ug/ml norfloxacin49cpxR_U_N0075_r1cpxR upregulation, 0.075 ug/ml norfloxacin49cpxR_U_N0075_r1cpxR upregulation, 0.075 ug/ml norfloxacin49crcB_U_N0075_r1crcB upregulation, 0.075 ug/ml norfloxacin49crcB_U_N0075_r1crcB upregulation, 0.075 ug/ml norfloxacin49crcB_U_N0075_r1crcB upregulation, 0.075 ug/ml norfloxacin49crcB_U_N0075_r1crcB upregulation, 0.075 ug/ml norfloxacin	at [8] at [8] at [8] at [8] TP TP TP TP TP TP TP TP TP
pepAA_t0_r2 strain BL21 (DE3) with T7 controllable synthetic peptide containing least abundant E. coli amino acids preinduction  pepCO_t0_r1 strain BL21 (DE3) with T7 controllable synthetic peptide containing most abundant E. coli amino acids preinduction  pepCO_t0_r2 strain BL21 (DE3) with T7 controllable synthetic peptide containing most abundant E. coli amino acids preinduction  pepCO_t30_r1 strain BL21 (DE3) with T7 controllable synthetic peptide containing most abundant E. coli amino acids preinduction with 1mM IPTG  b2618_U_N0075_r1 b2618 upregulation, 0.075 ug/ml norfloxacin  bcpU_N0075_r3 b2618 upregulation, 0.075 ug/ml norfloxacin  bcpU_N0075_r1 bcp upregulation, 0.075 ug/ml norfloxacin  bcpU_N0075_r1 cpxR upregulation, 0.075 ug/ml norfloxacin  cpxR_U_N0075_r1 cpxR upregulation, 0.075 ug/ml norfloxacin  crcB_U_N0075_r1 crcB upregulation, 0.075 ug/ml norfloxacin  crcB_U_N0075_r1 crcB upregulation, 0.075 ug/ml norfloxacin  crcB_U_N0075_r3 crcB upregulation, 0.075 ug/ml norfloxacin  crcB_U_N0075_r3 crcB upregulation, 0.075 ug/ml norfloxacin  crcB_U_N0075_r3 crcB upregulation, 0.075 ug/ml norfloxacin	nt [8] nt [8] nt [8] TP TP TP TP TP TP TP TP
48pepCO_t0_r1strain BL21 (DE3) with T7 controllable synthetic peptide containing most abunda E. coli amino acids preinduction48pepCO_t0_r2strain BL21 (DE3) with T7 controllable synthetic peptide containing most abunda E. coli amino acids preinduction48pepCO_t30_r1strain BL21 (DE3) with T7 controllable synthetic peptide containing most abunda E. coli amino acids 30 min postinduction with 1mM IPTG49b2618_U_N0075_r1b2618 upregulation, 0.075 ug/ml norfloxacin49b2618_U_N0075_r3b2618 upregulation, 0.075 ug/ml norfloxacin49bcpU_N0075_r1bcp upregulation, 0.075 ug/ml norfloxacin49cpxR_U_N0075_r1cpxR upregulation, 0.075 ug/ml norfloxacin49cpxR_U_N0075_r1cpxR upregulation, 0.075 ug/ml norfloxacin49crcB_U_N0075_r1crcB upregulation, 0.075 ug/ml norfloxacin49crcB_U_N0075_r1crcB upregulation, 0.075 ug/ml norfloxacin49crcB_U_N0075_r1crcB upregulation, 0.075 ug/ml norfloxacin49crcB_U_N0075_r3crcB upregulation, 0.075 ug/ml norfloxacin	nt [8]  TP  TP  TP  TP  TP  TP  TP  TP
pepCO_t0_r2 strain BL21 (DE3) with T7 controllable synthetic peptide containing most abunda E. coli amino acids preinduction  pepCO_t30_r1 strain BL21 (DE3) with T7 controllable synthetic peptide containing most abunda E. coli amino acids 30 min postinduction with 1mM IPTG  b2618_U_N0075_r1 b2618 upregulation, 0.075 ug/ml norfloxacin  b2618_U_N0075_r3 b2618 upregulation, 0.075 ug/ml norfloxacin  bcpU_N0075_r1 bcp upregulation, 0.075 ug/ml norfloxacin  bcpU_N0075_r3 bcp upregulation, 0.075 ug/ml norfloxacin  cpxR_U_N0075_r1 cpxR upregulation, 0.075 ug/ml norfloxacin  cpxR_U_N0075_r3 cpxR upregulation, 0.075 ug/ml norfloxacin  crcB_U_N0075_r1 crcB upregulation, 0.075 ug/ml norfloxacin  crcB_U_N0075_r1 crcB upregulation, 0.075 ug/ml norfloxacin  crcB_U_N0075_r3 crcB upregulation, 0.075 ug/ml norfloxacin	TP TP TP TP TP TP TP TP TP
strain BL21 (DE3) with T7 controllable synthetic peptide containing most abunda E. coli amino acids 30 min postinduction with 1mM IPTG  b2618_U_N0075_r1 b2618 upregulation, 0.075 ug/ml norfloxacin  b2618_U_N0075_r3 b2618 upregulation, 0.075 ug/ml norfloxacin  bcpU_N0075_r1 bcp upregulation, 0.075 ug/ml norfloxacin  bcpU_N0075_r3 bcp upregulation, 0.075 ug/ml norfloxacin  cpxRU_N0075_r1 cpxR upregulation, 0.075 ug/ml norfloxacin  cpxR_U_N0075_r3 cpxR upregulation, 0.075 ug/ml norfloxacin  crcB_U_N0075_r1 crcB upregulation, 0.075 ug/ml norfloxacin  crcB_U_N0075_r1 crcB upregulation, 0.075 ug/ml norfloxacin  crcB_U_N0075_r3 crcB upregulation, 0.075 ug/ml norfloxacin	TP TP TP TP TP TP TP
b2618_U_N0075_r3 b2618 upregulation, 0.075 ug/ml norfloxacin bcpU_N0075_r1 bcp upregulation, 0.075 ug/ml norfloxacin bcpU_N0075_r3 bcp upregulation, 0.075 ug/ml norfloxacin cpxR_U_N0075_r1 cpxR upregulation, 0.075 ug/ml norfloxacin cpxR_U_N0075_r3 cpxR upregulation, 0.075 ug/ml norfloxacin crcB_U_N0075_r1 crcB upregulation, 0.075 ug/ml norfloxacin crcB_U_N0075_r3 crcB upregulation, 0.075 ug/ml norfloxacin crcB_U_N0075_r3 crcB upregulation, 0.075 ug/ml norfloxacin	TP TP TP TP TP TP
bcpU_N0075_r1 bcp upregulation, 0.075 ug/ml norfloxacin bcpU_N0075_r3 bcp upregulation, 0.075 ug/ml norfloxacin cpxRU_N0075_r1 cpxR upregulation, 0.075 ug/ml norfloxacin cpxRU_N0075_r3 cpxR upregulation, 0.075 ug/ml norfloxacin crcB_U_N0075_r1 crcB upregulation, 0.075 ug/ml norfloxacin crcB_U_N0075_r3 crcB upregulation, 0.075 ug/ml norfloxacin crcB_U_N0075_r3 crcB upregulation, 0.075 ug/ml norfloxacin	TP TP TP TP
bcpU_N0075_r3 bcp upregulation, 0.075 ug/ml norfloxacin cpxRU_N0075_r1 cpxR upregulation, 0.075 ug/ml norfloxacin cpxRU_N0075_r3 cpxR upregulation, 0.075 ug/ml norfloxacin crcBU_N0075_r1 crcB upregulation, 0.075 ug/ml norfloxacin crcBU_N0075_r3 crcB upregulation, 0.075 ug/ml norfloxacin crcBU_N0075_r3 crcB upregulation, 0.075 ug/ml norfloxacin	TP TP TP TP
49 cpxR_U_N0075_r1 cpxR upregulation, 0.075 ug/ml norfloxacin 49 cpxR_U_N0075_r3 cpxR upregulation, 0.075 ug/ml norfloxacin 49 crcB_U_N0075_r1 crcB upregulation, 0.075 ug/ml norfloxacin 49 crcB_U_N0075_r3 crcB upregulation, 0.075 ug/ml norfloxacin	TP TP TP
cpxR_U_N0075_r3 cpxR upregulation, 0.075 ug/ml norfloxacin crcB_U_N0075_r1 crcB upregulation, 0.075 ug/ml norfloxacin crcB_U_N0075_r3 crcB upregulation, 0.075 ug/ml norfloxacin	TP TP
49 crcB_U_N0075_r1 crcB upregulation, 0.075 ug/ml norfloxacin 49 crcB_U_N0075_r3 crcB upregulation, 0.075 ug/ml norfloxacin	TP
49 crcB_U_N0075_r3 crcB upregulation, 0.075 ug/ml norfloxacin	
49 crp U N0075 r3 crp upregulation, 0.075 ug/ml norfloxacin	TP
· · · · · · · · · · · · · · · · · · ·	TP
49 cspF_U_N0075_r3 cspF upregulation, 0.075 ug/ml norfloxacin	TP
49 dnaA_U_N0075_r3 dnaA upregulation, 0.075 ug/ml norfloxacin	TP
49 dnaN_U_N0075_r3 dnaN upregulation, 0.075 ug/ml norfloxacin	TP
49 dnaT_U_N0075_r3 dnaT upregulation, 0.075 ug/ml norfloxacin	TP
49 eraU_N0075_r2 era upregulation, 0.075 ug/ml norfloxacin	TP
49 eraU_N0075_r3 era upregulation, 0.075 ug/ml norfloxacin	TP
49 fisU_N0075_r1 fis upregulation, 0.075 ug/ml norfloxacin	TP
49 fisU_N0075_r3 fis upregulation, 0.075 ug/ml norfloxacin	TP
49 fklB_U_N0075_r1 fklB upregulation, 0.075 ug/ml norfloxacin	TP
49 fklB_U_N0075_r2 fklB upregulation, 0.075 ug/ml norfloxacin	TP
49 fklB_U_N0075_r3 fklB upregulation, 0.075 ug/ml norfloxacin	TP
49 folA_U_N0075_r1 folA upregulation, 0.075 ug/ml norfloxacin	TP
49 folA_U_N0075_r3 folA upregulation, 0.075 ug/ml norfloxacin	TP
49 galF_U_N0075_r3 galF upregulation, 0.075 ug/ml norfloxacin	TP
49 gcvR_U_N0075_r3 gcvR upregulation, 0.075 ug/mL norfloxacin	TP
49 gyrA_U_N0075_r3 gyrA upregulation, 0.075 ug/mL norfloxacin	TP
49 hlpA_U_N0075_r3 hlpA upregulation, 0.075 ug/mL norfloxacin	TP
49 ldrA_U_N0075_r3 ldrA upregulation, 0.075 ug/mL norfloxacin	TP
49 mcrB_U_N0075_r1 mcrB upregulation, 0.075 ug/mL norfloxacin	TP
49 mcrB_U_N0075_r2 mcrB upregulation, 0.075 ug/mL norfloxacin	TP
49 mcrB_U_N0075_r3 mcrB upregulation, 0.075 ug/mL norfloxacin	TP
49 mcrC_U_N0075_r1 mcrC upregulation, 0.075 ug/mL norfloxacin	TP
49 mcrC_U_N0075_r2 mcrC upregulation, 0.075 ug/mL norfloxacin	TP
49 mcrC_U_N0075_r3 mcrC upregulation, 0.075 ug/mL norfloxacin	TP
49 menB_U_N0075_r3 menB upregulation, 0.075 ug/mL norfloxacin	TP
49 minE_U_N0075_r3 minE upregulation, 0.075 ug/mL norfloxacin	TP

49	pyrCU_N0075_r1	pyrC upregulation, 0.075 ug/mL norfloxacin	TP
49	pyrCU_N0075_r2	pyrC upregulation, 0.075 ug/mL norfloxacin	TP
49	pyrCU_N0075_r3	pyrC upregulation, 0.075 ug/mL norfloxacin	TP
49	rimIU_N0075_r2	rimI upregulation, 0.075 ug/mL norfloxacin	TP
49	uspAU_N0075_r3	uspA upregulation, 0.075 ug/mL norfloxacin	TP
50	b2618_U_N0075_r2	b2618 upregulation, 0.075 ug/ml norfloxacin	TP
50	crcBU_N0075_r2	crcB upregulation, 0.075 ug/ml norfloxacin	TP
50	crpU_N0075_r1	crp upregulation, 0.075 ug/ml norfloxacin	TP
50	eraU_N0075_r1	era upregulation, 0.075 ug/ml norfloxacin	TP
50	gyrAU_N0075_r2	gyrA upregulation, 0.075 ug/mL norfloxacin	TP
50	ldrAU_N0075_r1	ldrA upregulation, 0.075 ug/mL norfloxacin	TP
50	ldrAU_N0075_r2	ldrA upregulation, 0.075 ug/mL norfloxacin	TP
50	nupCU_N0075_r1	nupC upregulation, 0.075 ug/mL norfloxacin	TP
50	rstBU_N0075_r2	rstB upregulation, 0.075 ug/mL norfloxacin	TP
51	MGD1_t30_r1	strain BL21 (DE3) with mussel defensin protein MGD1 on T7 controllable plasmid 30 min postinduction with 1mM IPTG	[8]
52	pET3d_t30_r1	strain BL21 (DE3) with pET3d plasmid and no insert dna (makes 26 amino acid polypeptide) 30 min postinduction with 1 mM IPTG	[8]
52	pET3d_t30_r2	strain BL21 (DE3) with pET3d plasmid and no insert dna (makes 26 amino acid polypeptide) 30 min postinduction with 1 mM IPTG	[8]
52	pepAA_t30_r1	strain BL21 (DE3) with T7 controllable synthetic peptide containing least abundant E. coli amino acids 30 min postinduction with 1 mM IPTG	[8]
52	pepAA_t30_r2	strain BL21 (DE3) with T7 controllable synthetic peptide containing least abundant E. coli amino acids 30 min postinduction with 1 mM IPTG	[8]
52	pepCO_t30_r2	strain BL21 (DE3) with T7 controllable synthetic peptide containing most abundant E. coli amino acids 30 min postinduction with 1 mM IPTG	[8]
53	bcp U N0075 r2	bcp upregulation, 0.075 ug/ml norfloxacin	TP
53	cpxR U N0075 r2	cpxR upregulation, 0.075 ug/ml norfloxacin	TP
53	crpU_N0075_r2	crp upregulation, 0.075 ug/ml norfloxacin	TP
53	menBU_N0075_r2	menB upregulation, 0.075 ug/mL norfloxacin	TP
53	uspAU_N0075_r2	uspA upregulation, 0.075 ug/mL norfloxacin	TP
54	fnr_wtAnaerobic_r1	MG1655 OD 0.1 grown anaerobically	[6]
54	fnr_wtAnaerobic_r2	MG1655 OD 0.1 grown anaerobically	[6]
54	fnr_wtAnaerobic_r3	MG1655 OD 0.1 grown anaerobically	[6]
54	fnr_DfnrAnaerobic_r1	MG1655 with fnr deletion OD 0.1 grown anaerobically	[6]
54	fnr_DfnrAnaerobic_r2	MG1655 with fnr deletion OD 0.1 grown anaerobically	[6]
54	fnr_DfnrAnaerobic_r3	MG1655 with fnr deletion OD 0.1 grown anaerobically	[6]
54	fnr_DfnrAnaerobic_r4	MG1655 with fnr deletion OD 0.1 grown anaerobically	[6]
54	cybr_N_log_r1	BW30270 log phase, anaerobic on MOPS minimal media with glucose	[3]
54	cybr_N_log_r2	BW30270 log phase, anaerobic on MOPS minimal media with glucose	[3]
55	har_S0_R_noIPTG_r1	MG1655 with pPROEx-CAT plasmid late log phase in LB with glucose and MgSO <sub>4</sub>	[9]
55	har_S0_R_noIPTG_r4	MG1655 with pPROEx-CAT plasmid late log phase in LB with glucose and MgSO <sub>4</sub>	[9]
55	har_S0_R_noIPTG_r2	MG1655 with pPROEx-CAT plasmid late log phase in LB with glucose and MgSO <sub>4</sub>	[9]
55	har_S0_R_noIPTG_r5	MG1655 with pPROEx-CAT plasmid late log phase in LB with glucose and MgSO <sub>4</sub>	[9]
55	har_S0_R_noIPTG_r3	MG1655 with pPROEx-CAT plasmid late log phase in LB with glucose and MgSO <sub>4</sub>	[9]
55		MG1655 with pPROEx-CAT plasmid late log phase +1hr in LB with glucose and MgSO4	[9]
55	har_S1_R_noIPTG_r2	MG1655 with pPROEx-CAT plasmid late log phase +1hr in LB with glucose and MgSO4	[9]
55	har_S1_R_noIPTG_r3	MG1655 with pPROEx-CAT plasmid late log phase +1hr in LB with glucose and MgSO4	[9]
55	har_S0_noIPTG_r1	MG1655 late log phase in LB with glucose and MgSO <sub>4</sub>	[9]
55	har_S0_noIPTG_r2	MG1655 late log phase in LB with glucose and MgSO <sub>4</sub>	[9]
	~ ··		r. 1

55	har_S0_noIPTG_r3	MG1655 late log phase in LB with glucose and MgSO <sub>4</sub>	[9]
55	har_S1_noIPTG_r1	MG1655 late log phase +1hr in LB with glucose and MgSO <sub>4</sub>	[9]
55	har_S1_noIPTG_r2	MG1655 late log phase +1hr in LB with glucose and MgSO <sub>4</sub>	[9]
55	har_S1_noIPTG_r3	MG1655 late log phase +1hr in LB with glucose and MgSO <sub>4</sub>	[9]
55	har_S4_noIPTG_r1	MG1655 late log phase +4hr in LB with glucose and MgSO <sub>4</sub>	[9]
55	har_S4_noIPTG_r2	MG1655 late log phase +4hr in LB with glucose and MgSO <sub>4</sub>	[9]
55	har_S4_noIPTG_r3	MG1655 late log phase +4hr in LB with glucose and MgSO <sub>4</sub>	[9]
55	har_S1_IPTG_r1	MG1655 late log phase +1hr in LB with glucose and MgSO <sub>4</sub> and IPTG	[9]
55	har_S1_IPTG_r2	MG1655 late log phase +1hr in LB with glucose and MgSO <sub>4</sub> and IPTG	[9]
55	har_S1_IPTG_r3	MG1655 late log phase +1hr in LB with glucose and MgSO <sub>4</sub> and IPTG	[9]
55	har_S4_IPTG_r1	MG1655 late log phase +4hr in LB with glucose and MgSO <sub>4</sub> and IPTG	[9]
55	har_S4_IPTG_r2	MG1655 late log phase +4hr in LB with glucose and MgSO <sub>4</sub> and IPTG	[9]
55	har_S4_IPTG_r3	MG1655 late log phase +4hr in LB with glucose and MgSO <sub>4</sub> and IPTG	[9]
56	har_S4_R_noIPTG_r1	MG1655 with pPROEx-CAT plasmid late log phase +4hr in LB with glucose and MgSO4	[9]
56	har_S4_R_noIPTG_r2	MG1655 with pPROEx-CAT plasmid late log phase +4hr in LB with glucose and MgSO4	[9]
56	har_S4_R_noIPTG_r3	MG1655 with pPROEx-CAT plasmid late log phase +4hr in LB with glucose and MgSO4	[9]
56	har_S1_R_IPTG_r1	MG1655 with pPROEx-CAT plasmid late log phase +1hr in LB with glucose and MgSO4 and IPTG	[9]
56	har_S1_R_IPTG_r2	MG1655 with pPROEx-CAT plasmid late log phase +1hr in LB with glucose and MgSO4 and IPTG	[9]
56	har_S1_R_IPTG_r3	MG1655 with pPROEx-CAT plasmid late log phase +1hr in LB with glucose and MgSO4 and IPTG	[9]
56	har_S4_R_IPTG_r1	MG1655 with pPROEx-CAT plasmid late log phase +4hr in LB with glucose and MgSO4 and IPTG	[9]
56	har_S4_R_IPTG_r2	MG1655 with pPROEx-CAT plasmid late log phase +4hr in LB with glucose and MgSO4 and IPTG	[9]
56	har_S4_R_IPTG_r3	MG1655 with pPROEx-CAT plasmid late log phase +4hr in LB with glucose and MgSO4 and IPTG	[9]
57	cybr_KNO_N_r1	MG1655 log phase, anaerobic with nitrate on MOPS minimal media with glucose	[3]
57	cybr_KNO_N_r2	MG1655 log phase, anaerobic with nitrate on MOPS minimal media with glucose	[3]
57	cybr_N_r1	MG1655 log phase, anaerobic on MOPS minimal media with glucose	[3]
57	cybr_N_r2	MG1655 log phase, anaerobic on MOPS minimal media with glucose	[3]
58	ik_L2_T2.5_r1	K12 EMG2 on LB with 0.2 percent glucose, 2.5 hours post-incubation	TP
58	ik_L2_T3_r1	K12 EMG2 on LB with 0.2 percent glucose, 3 hours post-incubation	TP
58	ik_L2_T3.5_r1	K12 EMG2 on LB with 0.2 percent glucose, 3.5 hours post-incubation	TP
58	ik_L2_T4_r1	K12 EMG2 on LB with 0.2 percent glucose, 4 hours post-incubation	TP
58	ik_L2_T4.5_r1	K12 EMG2 on LB with 0.2 percent glucose, 4.5 hours post-incubation	TP
58	ik_H2_T2.5_r1	K12 EMG2 on LB with 0.4 percent glucose, 2.5 hours post-incubation	TP
58	ik_H2_T3_r1	K12 EMG2 on LB with 0.4 percent glucose, 3 hours post-incubation	TP
58	ik_H2_T3.5_r1	K12 EMG2 on LB with 0.4 percent glucose, 3.5 hours post-incubation	TP
59	ik_L2_T5_r1	K12 EMG2 on LB with 0.2 percent glucose, 5 hours post-incubation	TP
59	ik_L2_T5.5_r1	K12 EMG2 on LB with 0.2 percent glucose, 5.5 hours post-incubation	TP
59	ik_L2_T6_r1	K12 EMG2 on LB with 0.2 percent glucose, 6 hours post-incubation	TP
59	ik_H2_T4_r1	K12 EMG2 on LB with 0.4 percent glucose, 4 hours post-incubation	TP
59	ik_H2_T4.5_r1	K12 EMG2 on LB with 0.4 percent glucose, 4.5 hours post-incubation	TP
59	ik_H2_T5_r1	K12 EMG2 on LB with 0.4 percent glucose, 5 hours post-incubation	TP
59	ik_H2_T5.5_r1	K12 EMG2 on LB with 0.4 percent glucose, 5.5 hours post-incubation	TP
59	ik_H2_T6_r1	K12 EMG2 on LB with 0.4 percent glucose, 6 hours post-incubation	TP
59	ik_H2_T8_r1	K12 EMG2 on LB with 0.4 percent glucose, 8 hours post-incubation	TP
60	ik_L2_T8_r1	K12 EMG2 on LB with 0.2 percent glucose, 8 hours post-incubation	TP

Experiments were clustered with the complete-linkage algorithm using inverse CLR scores computed for the microarrays (not the genes) as the pairwise distance metric. The tree was pruned at 60 clusters.

### Table S4 References

- 1. Maurer LM, Yohannes E, Bondurant SS, Radmacher M, Slonczewski JL (2005) pH regulates genes for flagellar motility, catabolism, and oxidative stress in Escherichia coli K-12. J Bacteriol 187: 304-319.
- 2. Covert MW, Knight EM, Reed JL, Herrgard MJ, Palsson BO (2004) Integrating high-throughput and computational data elucidates bacterial networks. Nature 429: 92-96
- 3. Brokx SJ, Ellison M, Locke T, Bottorff D, Frost L, et al. (2004) Genome-wide analysis of lipoprotein expression in Escherichia coli MG1655. J Bacteriol 186: 3254-3258.
- 4. Allen TE, Herrgard MJ, Liu M, Qiu Y, Glasner JD, et al. (2003) Genome-scale analysis of the uses of the Escherichia coli genome: model-driven analysis of heterogeneous data sets. J Bacteriol 185: 6392-6399.
- 5. Herring CD, Blattner FR (2004) Global transcriptional effects of a suppressor tRNA and the inactivation of the regulator frmR. J Bacteriol 186: 6714-6720.
- 6. Kang Y, Weber KD, Qiu Y, Kiley PJ, Blattner FR (2005) Genome-wide expression analysis indicates that FNR of Escherichia coli K-12 regulates a large number of genes of unknown function. J Bacteriol 187: 1135-1160.
- 7. Liu M, Durfee T, Cabrera JE, Zhao K, Jin DJ, et al. (2005) Global transcriptional programs reveal a carbon source foraging strategy by Escherichia coli. J Biol Chem 280: 15921-15927.
- 8. Bonomo J, Gill RT (2005) Amino acid content of recombinant proteins influences the metabolic burden response. Biotechnol Bioeng 90: 116-126.
- 9. Haddadin FT, Harcum SW (2005) Transcriptome profiles for high-cell-density recombinant and wild-type Escherichia coli. Biotechnol Bioeng 90: 127-153.

1.64)	48.4375				
% significant (z >=					
yrbA_b3190_at	10	0.19			
yneJ_b1526_at	6	-0.41			
ynaE_b1375_s_at	8	5.34			
ymfN_b1149_at	6	1.79			
ymfL_b1147_at	7	0.84			
yjbK_b4046_at	10	1.34			
yjaE_b3995_at	6	1.44			
yihL_b3872_at	5	0.88			
yidW_b3695_at	5	-0.47			
yidF_b3674_at	9	0.49			
yhjB_b3520_at	10	2.85			CysB(1)
yhiX_b3516_at	16	4.21	4	PRODORIC	
yhiW_b3515_at	9	-0.09			yhiX(19)
yhiF_b3507_at	9	3.70			YhiX(7)
yhiE_b3512_at	20	3.30			YhiX(13)
yheN_b3345_at	6	0.83			
ygeK_b2855_at	8	0.35			
yfeD_b2399_at	6	0.23			

# **Supplementary Tables**

Table S5. Functional categories with >= 3 unconnected transcription factors at 60% precision

Functional category*	Transcription factors	Count
primary metabolism	ada, asnC, cysB, metJ, metR, mlc,	8
	prpR, uidA	
prophage genes and phage related functions	appY, dicA, dicC, pspF, yagI, ydaS,	7
	yfjR	
regulation of cellular metabolism	nagC, ycfQ, ydhB, yeaM, yjhU, ynfL,	7
	yphH	
energy metabolism, carbon	fhlA, glpR, gntR, hyfR, narP, torR	6
regulation of transcription, DNA-dependent	ycfQ, ydhB, yeaM, yjhU, ynfL, yphH	6
regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism	ycfQ, ydhB, yeaM, yjhU, ynfL, yphH	6
cellular biosynthesis	asnC, cysB, metJ, metR, mlc, modE	6
biosynthesis	asnC, cysB, metJ, metR, mlc, modE	6
energy derivation by oxidation of organic compounds	fhlA, glpR, hyfR, narP, torR	5
carboxylic acid metabolism	asnC, cysB, metJ, metR, prpR	5
generation of precursor metabolites and energy	fhlA, glpR, hyfR, narP, torR	5
organic acid metabolism	asnC, cysB, metJ, metR, prpR	5
Transcription related	arcA, creB, kdpE, ompR	4
RNA related	arcA, creB, kdpE, ompR	4
anaerobic respiration	glpR, hyfR, narP, torR	4
carbon utilization	atoC, caiF, putA, uhpA	4
cellular respiration	glpR, hyfR, narP, torR	4
sulfur metabolism	aslB, cysB, metJ, metR	4
amino acid and derivative metabolism	asnC, cysB, metJ, metR	4
amino acid biosynthesis	asnC, cysB, metJ, metR	4
amine biosynthesis	asnC, cysB, metJ, metR	4
amino acid metabolism	asnC, cysB, metJ, metR	4
nitrogen compound biosynthesis	asnC, cysB, metJ, metR	4
amine metabolism	asnC, cysB, metJ, metR	4
nitrogen compound metabolism	asnC, cysB, metJ, metR	4
response to stimulus	ada, cspE, rpoH, ycaL	4
type of regulation	ybhN, yddM, yjjQ	3
nucleoproteins, basic proteins	hns, hupA, hupB	3
protein related	hns, hupA, hupB	3
biosynthesis of building blocks	birA, putA, trpR	3
response to temperature stimulus	cspE, rpoH, ycaL	3
response to abiotic stimulus	cspE, rpoH, ycaL	3
sulfur compound biosynthesis	cysB, metJ, metR	3
aspartate family amino acid biosynthesis	asnC, metJ, metR	3
sulfur amino acid biosynthesis	cysB, metJ, metR	3
aspartate family amino acid metabolism	asnC, metJ, metR	3
sulfur amino acid metabolism	cysB, metJ, metR	3
macromolecule metabolism	ada, mlc, uidA	3

<sup>\*</sup> generic / nonspecific GO terms have been removed

Table S6. Functional categories with >= 15 unconnected genes at 60% precision.

Functional Category*	Count
nucleobase, nucleoside, nucleotide and nucleic acid metabolism	191
transport	186
biopolymer metabolism	171
biosynthesis	169
cellular biosynthesis	168
energy metabolism, carbon	135
energy derivation by oxidation of organic compounds	135
generation of precursor metabolites and energy	135
organic acid metabolism	135
carboxylic acid metabolism	133
biosynthesis of building blocks	113
extrachromosomal	109
carbon utilization	107
cellular respiration	100
prophage genes and phage related functions	99
nitrogen compound metabolism	96
amine metabolism	94
amino acid and derivative metabolism	90
biosynthesis of macromolecules (cellular constituents)	86
central intermediary metabolism	85
Channel-type Transporters	79
carbohydrate metabolism	76
amino acid metabolism	76
Pyrophosphate Bond (ATP; GTP; P2) Hydrolysis-driven Active Transporters	75
catabolism	74
cellular macromolecule metabolism	69
The ATP-binding Cassette (ABC) Superfamily + ABC-type Uptake Permeases	68
anaerobic respiration	66
carbon compounds	65
Porters (Uni-, Sym- and Antiporters)	64
Electrochemical potential driven transporters	64
RNA metabolism	64
translation	59
biopolymer modification	55
DNA metabolism	55
macromolecule catabolism	55
cofactor metabolism	52
amine biosynthesis	52
nitrogen compound biosynthesis	52
cellular protein metabolism	49
protein metabolism	49
response to stimulus	47
cofactor biosynthesis	46
location of gene products	45
coenzyme metabolism	45
RNA modification	44

cellular carbohydrate metabolism	44
amino acid biosynthesis	44
transcriptional activator activity	44
water-soluble vitamin metabolism	42
nucleobase, nucleoside and nucleotide interconversion	42
vitamin metabolism	42
cellular catabolism	42
establishment of localization	41
coenzyme biosynthesis	39
	36
cell structure	
membrane	34
aerobic respiration	34
lipid metabolism	34
cellular lipid metabolism	34
carbohydrate catabolism	32
water-soluble vitamin biosynthesis	31
vitamin biosynthesis	31
macromolecule biosynthesis	31
response to stress	30
carbohydrate biosynthesis	29
transcriptional repressor activity	29
DNA replication	28
aromatic compound metabolism	27
ABC superfamily, membrane component	26
lipopolysaccharide	26
polysaccharide metabolism	26
ABC superfamily ATP binding cytoplasmic component	25 25
outer membrane (sensu Gram-negative Bacteria)	23
murein (peptidoglycan) amines	24
tRNA modification	24
tRNA metabolism	24
tRNA aminoacylation for protein translation	24
amino acid activation	24
inner membrane	23
response to abiotic stimulus	23
cytokinesis	23
cell division	23
cellular macromolecule catabolism	23
regulation of transcription, DNA-dependent	22
regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism	22
biopolymer catabolism	22
DNA-dependent DNA replication	21
aromatic compound biosynthesis	21
nucleotide metabolism	20
main pathways of carbohydrate metabolism	20
cellular polysaccharide metabolism	20
nucleotide biosynthesis	20
polysaccharide biosynthesis	20
biopolymer biosynthesis	20
cytonlasm	19

fatty acid oxidation	19
fatty acid metabolism	19
protein folding	19
cellular_component	19
phosphorous metabolism	18
heterocycle metabolism	18
sulfur metabolism	18
alcohol metabolism	18
intracellular non-membrane-bound organelle	18
intracellular organelle	18
non-membrane-bound organelle	18
organelle	18
DNA repair	17
response to DNA damage stimulus	17
response to endogenous stimulus	17
oxidoreduction coenzyme metabolism	17
glycoprotein metabolism	17
amino acid derivative metabolism	16
rRNA metabolism	16
proteolysis	16
glycopeptide catabolism	16
glycoprotein catabolism	16
proteolysis during cellular protein catabolism	16
cellular protein catabolism	16
protein catabolism	16
protection	15
fermentation	15
phospholipid metabolism	15
membrane lipid metabolism	15
pteridine and derivative metabolism	15
pteridine and derivative biosynthesis	15
carboxylic acid biosynthesis	15
organic acid biosynthesis	15
phospholipid biosynthesis	15
membrane lipid biosynthesis	15
lipid biosynthesis	15
transporter activity	15

<sup>\*</sup> generic / nonspecific GO terms have been removed

### **Protocol S1 References**

- 1. Walker GC (1996) The SOS Response of *Escherichia coli*. In: Neidhardt FC, Curtiss R, editors. Escherichia coli and Salmonella: cellular and molecular biology. 2nd ed. Washington, D.C.: ASM Press.
- 2. Margolin AA, Nemenman I, Basso K, Wiggins C, Stolovitzky G, et al. (2006) ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context. BMC Bioinformatics 7 Suppl 1: S7.
- 3. Hartemink AJ (2005) Reverse engineering gene regulatory networks. Nat Biotechnol 23: 554-555.
- 4. Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla-Favera R, et al. (2005) Reverse engineering of regulatory networks in human B cells. Nat Genet 37: 382-390.
- 5. Shen-Orr SS, Milo R, Mangan S, Alon U (2002) Network motifs in the transcriptional regulation network of Escherichia coli. Nat Genet 31: 64-68.
- 6. Hartemink AJ, Gifford DK, Jaakkola TS, Young RA (2002) Combining location and expression data for principled discovery of genetic regulatory network models. Pac Symp Biocomput: 437-449.
- 7. Murphy K (2001) The Bayes Net Toolbox for Matlab. Computing Science and Statistics 33.
- 8. Friedman N, Linial M, Nachman I, Pe'er D (2000) Using Bayesian networks to analyze expression data. J Comput Biol 7: 601-620.
- 9. Butte AJ, Tamayo P, Slonim D, Golub TR, Kohane IS (2000) Discovering functional relationships between RNA expression and chemotherapeutic susceptibility using relevance networks. Proc Natl Acad Sci U S A 97: 12182-12186.
- 10. Butte AJ, Kohane IS (2000) Mutual information relevance networks: functional genomic clustering using pairwise entropy measurements. Pac Symp Biocomput: 418-429.
- 11. Roulston M (1997) Significance testing of information theoretic functionals. Physica D Volume 110, Number 1: 62-66 (65).
- 12. Qian J, Lin J, Luscombe NM, Yu H, Gerstein M (2003) Prediction of regulatory networks: genome-wide identification of transcription factor targets from gene expression data. Bioinformatics 19: 1917-1926.
- 13. Liang S, Fuhrman S, Somogyi R (1998) Reveal, a general reverse engineering algorithm for inference of genetic network architectures. Pac Symp Biocomput: 18-29.
- 14. de la Fuente A, Brazhnik P, Mendes P (2002) Linking the genes: inferring quantitative gene networks from microarray data. Trends Genet 18: 395-398.

- 15. Ideker T, Thorsson V, Ranish JA, Christmas R, Buhler J, et al. (2001) Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science 292: 929-934.
- 16. Wagner A (2001) How to reconstruct a large genetic network from n gene perturbations in fewer than n(2) easy steps. Bioinformatics 17: 1183-1197.
- 17. Tringe SG, Wagner A, Ruby SW (2004) Enriching for direct regulatory targets in perturbed gene-expression profiles. Genome Biol 5: R29.
- 18. Ideker TE, Thorsson V, Karp RM (2000) Discovery of regulatory interactions through perturbation: inference and experimental design. Pac Symp Biocomput: 305-316.
- 19. D'Haeseleer P, Liang S, Somogyi R (2000) Genetic network inference: from co-expression clustering to reverse engineering. Bioinformatics 16: 707-726.
- 20. Bonneau R, Reiss DJ, Shannon P, Facciotti M, Hood L, et al. (2006) The Inferelator: an algorithm for learning parsimonious regulatory networks from systems-biology data sets de novo. Genome Biol 7: R36.
- 21. D'Haeseleer P, Wen X, Fuhrman S, Somogyi R (1999) Linear modeling of mRNA expression levels during CNS development and injury. Pac Symp Biocomput: 41-52.
- 22. Bansal M, Gatta GD, di Bernardo D (2006) Inference of gene regulatory networks and compound mode of action from time course gene expression profiles. Bioinformatics 22: 815-822.
- 23. Kaeberlein T, Lewis K, Epstein SS (2002) Isolating "uncultivable" microorganisms in pure culture in a simulated natural environment. Science 296: 1127-1129.
- 24. Mashburn LM, Whiteley M (2005) Membrane vesicles traffic signals and facilitate group activities in a prokaryote. Nature 437: 422-425.
- 25. Vlamakis HC, Kolter R (2005) Thieves, assassins and spies of the microbial world. Nat Cell Biol 7: 933-934.
- 26. Xavier KB, Bassler BL (2005) Interference with AI-2-mediated bacterial cell-cell communication. Nature 437: 750-753.
- 27. Box GEP, Hunter WG, Hunter JS (1978) Statistics for experimenters: an introduction to design, data analysis, and model building. New York: Wiley. xviii, 653 p.
- 28. Fisher RA (1966) The design of experiments. New York: Hafner Pub. Co. xv, 248 p.
- 29. Kerr MK, Churchill GA (2001) Experimental design for gene expression microarrays. Biostatistics 2: 183-201.
- 30. Scholtens D, Miron A, Merchant FM, Miller A, Miron PL, et al. (2004) Analyzing factorial

- designed microarray experiments. Journal of Multivariate Analysis 90: 19-43.
- 31. Gardner TS, Faith JJ (2005) Reverse-engineering transcription control networks. Physics of Life Reviews 2: 65-88.
- 32. Draghici S, Khatri P, Eklund AC, Szallasi Z (2006) Reliability and reproducibility issues in DNA microarray measurements. Trends Genet 22: 101-109.
- 33. Balazsi G, Barabasi AL, Oltvai ZN (2005) Topological units of environmental signal processing in the transcriptional regulatory network of Escherichia coli. Proc Natl Acad Sci U S A 102: 7841-7846.
- 34. Salgado H, Gama-Castro S, Peralta-Gil M, Diaz-Peredo E, Sanchez-Solano F, et al. (2006) RegulonDB (version 5.0): Escherichia coli K-12 transcriptional regulatory network, operon organization, and growth conditions. Nucleic Acids Res 34: D394-397.
- 35. Carty SM, Sreekumar KR, Raetz CR (1999) Effect of cold shock on lipid A biosynthesis in Escherichia coli. Induction At 12 degrees C of an acyltransferase specific for palmitoleoyl-acyl carrier protein. J Biol Chem 274: 9677-9685.
- 36. Xia B, Ke H, Inouye M (2001) Acquirement of cold sensitivity by quadruple deletion of the cspA family and its suppression by PNPase S1 domain in Escherichia coli. Mol Microbiol 40: 179-188.
- 37. Bailey TL, Elkan C (1994) Fitting a mixture model by expectation maximization to discover motifs in biopolymers. Proc Int Conf Intell Syst Mol Biol 2: 28-36.
- 38. Munch R, Hiller K, Barg H, Heldt D, Linz S, et al. (2003) PRODORIC: prokaryotic database of gene regulation. Nucleic Acids Res 31: 266-269.
- 39. Lin DC, Grossman AD (1998) Identification and characterization of a bacterial chromosome partitioning site. Cell 92: 675-685.
- 40. Gardner TS, di Bernardo D, Lorenz D, Collins JJ (2003) Inferring genetic networks and identifying compound mode of action via expression profiling. Science 301: 102-105.